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Abstract
Purpose: To determine the efficacy of selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) levels and reducing the number of medications in patients with open
angle glaucoma (OAG) or ocular hypertension (OHT).
Methods: A systematic review was conducted by searching various databases including
MEDLINE (Ovid), EMBASE (Ovid), CINAHL, Cochrane Library, Web of Science- Core
Collections, BIOSIS Previews, and Scopus. Duplicates were removed and articles were
screened using EPPI Reviewer 4. A meta-analysis was conducted using STATA 13.0.
Weighted mean difference (WMD) was computed and the heterogeneity statistic was
assessed using the I2. Fixed and random effects models were computed based on
heterogeneity.
Results: We identified 31 articles that met our inclusion criteria. We found that Sequential
SLT versus pharmacotherapy had an IOP-lowering effect favoring pharmacotherapy: WMD=
5.92% (95% CI [3.06, 8.79]) and WMD= 2.73% (95% CI [0.24, 5.23]) at 6 and 12 months,
respectively. Adjunctive SLT had a greater IOP-lowering effect compared to
pharmacotherapy, WMD= -8.98% (95% CI [-17.19, -0.77]). A significant reduction in the
post-operative medications was observed up to 17 months. No serious complications were
reported.
Conclusion: Adjunctive SLT may lead to significant reduction in IOP compared to topical
medications. Additional studies need to be conducted on SLT alone, without previous
treatment in order to determine its IOP-lowering effect.

Keywords
Open-angle glaucoma, Ocular hypertension, Intra-ocular pressure, Selective laser
trabeculoplasty, Prostaglandin analogs, Beta-blockers, Carbonic anhydrase inhibitors, Alpha
agonists, Pharmacotherapy
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Chapter 1

1.1 Introduction
This thesis aims to evaluate selective laser trabeculoplasty (SLT) as an intervention to
treat patients who are diagnosed with open-angle glaucoma (OAG) or ocular
hypertension (OHT). Ophthalmologists use glaucoma medications as their primary form
of treatment for glaucoma patients1, due to robust data supporting their efficacy2–10. SLT
is a laser treatment option that was introduced by Dr. Latina and colleagues in 199511.The
first clinical study published that reported on the efficacy of SLT was in 199812. Over the
past two decades, there has been a vast amount of literature that has been published on
the efficacy of SLT. We conducted this systematic review and meta-analysis with the
intention of assessing the influence of SLT on intra-ocular pressure (IOP) levels and its
impact on reducing the amount of required topical glaucoma medications.

1.2 Epidemiology of Glaucoma
Glaucoma is the second most common cause of legal blindness in industrialized
nations13. In 2013, the worldwide prevalence of glaucoma for a population aged 40 to 80
years was estimated to be approximately 3.54% (95% CI [2.09%, 5.82%]) of the global
population14. Specifically, in North America, the prevalence of glaucoma was estimated
to be 3.55% (95% CI [1.98%, 5.81%])14. The incidence is estimated to be approximately
0.5 to 2.5% per year15. By 2020 there will be approximately 79.6 million people
estimated to be affected by glaucoma worldwide and 11,114,117 people (95% CI [7 947
390, 16 230 278]) will become bilaterally blind from glaucoma16. By the year 2040, the
global prevalence of glaucoma is expected to rise to 111.8 million14.

The prevalence numbers are assumed to be underestimated given that approximately onethird of individuals with glaucoma are undiagnosed17. If glaucoma goes untreated, it can
lead to blindness. Glaucoma is one of the top three causes of visual impairment and
blindness worldwide18. The percentage of people who go blind per year because of

2

glaucoma is approximately 0.55%15.Blindness is defined as a visual acuity score of less
than 3/6019, which means that what a person sees at three meters, a person with normal
vision sees at 60 meters. Since more than 80% of visual impairment is avoidable18, not
diagnosing and not treating glaucoma puts an unnecessary strain on the health care
system.

1.3 Organization of Thesis
This thesis is organized into four main sections. Chapter 2 provides a detailed literature
review including the history of glaucoma, the types and treatment of glaucoma, the costs
associated with glaucoma treatment, and the purpose and objectives of this thesis. Chapter
3 provides details on the methodological approach used to investigate the research
questions. It discusses the search strategies, inclusion and exclusion criteria, the article
screening process, and the quantitative measures used to analyze the results. Chapter 4
provides figures, tables and a summary of the results produced. Chapter 5 provides a
comprehensive discussion on the results including the overall interpretation of the findings,
the strengths and limitations, and future policy and research implications.
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Chapter 2

2

Literature Review
2.1 Definition and History of Glaucoma

“Glaucoma” comes from the Greek word glaucosis, which is defined as the ‘blue-green
hue of the affected eye’20. In the 10th century, Arabian physicians noted the connection
between glaucoma and increased pressure inside the eye. In 1622, Richard Bannister
noted that chronic glaucoma could be associated with elevated intraocular pressure, and
was the first to document these findings in English21. From the 10th century to the 19th
century, ophthalmologists from around the world have noted similar characteristics of
increased pressure inside the eye. Elevated intra-ocular pressure (IOP) levels were
accepted as a distinguishing symptom of glaucoma in the mid-19th century21.
Several clinical studies conducted in the 1990s have shown that many glaucoma cases
had other causes besides elevated intraocular pressure levels20. The definition of
glaucoma shifted from being solely defined by elevated IOP levels to being defined by its
optic nerve damage and associated vision loss20.

2.2 Pathophysiology of Glaucoma
A clear fluid referred to as the aqueous humor is produced by the ciliary body and fills
the anterior and posterior chambers of the eye22. The rate of fluid production is
approximately 2.5 microliters/minute22. Fluid inside the eye must be under some
pressure at all times to keep it from collapsing. The fluid exits the anterior chamber
through the trabecular meshwork (TM) or the uveoscleral outflow. The TM is a spongelike structure which consists of three layers23. The resistance to fluid outflow increases as
fluid passes each layer of the TM and enters the Schlemm’s canal. Fluid that does not
flow to the TM, flows into the supraciliary space and ciliary muscle and then goes to the
scleral substance or the emissarial canals or is absorbed into the uveal blood vessel; this
outflow is called the uveoscleral outflow24. The uveoscleral outflow only accounts for
approximately 4 to 45% of aqueous humor outflow24. Treatment is aimed at the TM
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because the TM outflow is IOP dependent, while the uveoscleral outflow is independent
of IOP24.
Too much pressure caused from not having enough fluid exiting the eye may result in
elevated eye pressures. Pressure on the optic nerve may result in optic nerve damage22.
The optic nerve is located at the back of the eye and has approximately 1.2 million nerve
fibers25. The optic nerve travels from the back of each eye and joins together at the optic
chiasm22. Electrical impulses travel along the optic nerve, optic tract, lateral geniculate
body and finally the occipital lobe where the images are interpreted by the brain22. Due to
the damage of the optic nerve, the retinal nerve cells eventually die, disrupting the
connection between the eye and the brain26, resulting in vision loss.
The main distinguishing feature from other neuropathic diseases is that the presence of
glaucoma results in a progressively large optic nerve cup25. As the optic nerve loses nerve
fibers, the cup becomes larger. The cup-to-disc ratio ranges from 0 to 125. The larger the
cup-to-disc ratio, the larger the optic nerve damage. Another factor that makes glaucoma
different from other neuropathic diseases is that the treatment is aimed at lowering the
intra-ocular pressure, whereas other neuropathic diseases usually have normal intraocular pressure levels.

2.3

Types of Glaucoma

The majority of glaucoma diseases fall under one of three categories: open-angle
glaucoma (OAG), ocular hypertension (OHT) and angle closure glaucoma. This thesis
will focus on OAG and OHT.

2.3.1

Open-angle Glaucoma

The drainage angle, which is located between the cornea and the iris, is what determines
whether a patient has open-angle glaucoma or closed-angle glaucoma27. If the drainage
angle is open, this is referred to as OAG. OAG is generally a bilateral disease, but may
often also be asymmetric28. OAG is characterized as either primary or secondary. Primary
OAG accounts for almost 90% of all glaucoma cases5. Secondary OAG is any form of
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OAG that has an identifiable cause22. Patients with OAG who have IOP levels greater
than 21 mm Hg are referred to as high tension glaucoma patients27. Patients with
glaucomatous nerve damage, who have IOP levels lower than 22 mm Hg, account for
approximately 15% of all OAG cases28. These patients are referred to as normal tension
glaucoma (NTG) patients. OAG is usually asymptomatic and patients may notice a loss
of peripheral vision after approximately 40% of nerve fibers have been damaged28.

2.3.2

Ocular Hypertension

Ocular hypertensive (OHT) patients have an open drainage angle and have IOP levels
over 21 mm Hg. They do not show signs of optic nerve damage or visual field defects29;
this group of patients are referred to as glaucoma suspects22.

2.3.3

Angle Closure Glaucoma

Angle closure glaucoma (ACG) is a less common form of glaucoma, and has a drainage
angle that is closed when it is examined by the gonioscopy lens25. ACG is also
characterized as primary or secondary. Primary ACG occurs when there is a pupillary
block that cause the angle to close22. Secondary ACG is when there are underlying
reasons other than a pupillary block that causes the angle to close. This type of glaucoma
may be associated with symptoms of pain, nausea and decreased vision25.
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2.4 Glaucoma Risk Factors
There are several different risk factors associated with the development of glaucoma. The
risk factors are divided into three different groups: elevated IOP, demographic factors,
and medical factors.

2.4.1

Intraocular Pressure (IOP)

Intraocular pressure (IOP) refers to the fluid pressure in the eye30. High IOP levels, IOP
levels above 21 mm Hg, is not a necessary cause for developing glaucoma, but it does
increase the likelihood of developing the disease25. The Baltimore Eye Survey and the
Barbados Eye Study found that IOP was an important factor correlated with higher
prevalence and incidence rates31. It has been well-documented that the relative risk of
developing glaucoma increases as an individual’s IOP levels increase25.
Approximately26.1% of patients who have IOP levels greater than or equal to 35mm Hg
have glaucoma versus only 0.7% of patients who have IOP levels less than 15mm Hg
have glaucoma25. Also, those who have an IOP asymmetry between their eyes have a
higher likelihood of developing glaucoma20.

2.4.2

Demographic Factors

Age is one of the strongest determining factors for developing glaucoma, as the
frequency of glaucoma cases increases with age20. The majority of glaucoma cases
develop after the age of 40 or 50 years32. The American Academy of Ophthalmology has
recommended that those between 40 and 64 get assessed for glaucoma every 2-4 years
and those over the age of 65 get assessed every 1-2 years25. The reason for the increase in
risk with increasing age is that nerve fibers are lost throughout one’s lifetime26. The more
nerve fibers are lost, the wider the cup-to-disc ratio becomes resulting in an increased risk
of developing glaucoma22. Race also plays a role in the prevalence of glaucoma cases. It
has been reported that African Americans are more likely than Caucasians to develop
primary open-angle glaucoma and to become blind from it25. Asians are more likely to
develop primary angle closure glaucoma (PACG)16. Approximately 0.3 to 2.6% of Asians
will develop PACG compared to 0.1% to 0.6% of all other races25.
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2.4.3

Medical Factors

Diseases such as thyroid disease, obesity, diabetes, emphysema and cardiovascular
disease are risk factors that may lead to glaucoma20. There is a strong positive correlation
between taking steroids and developing glaucoma20. The IOP levels are elevated in
approximately 16% of those on steroids20. Also, if there is a history of glaucoma in one’s
family, the likelihood of developing glaucoma will increase32. To an extent, an
individual’s genetic code can determine whether they can tolerate a high IOP level26.

2.5 Assessment of Glaucoma
Early detection of the disease is essential to prevent as much vision loss as possible.
There are several measurement tools that ophthalmologists use to accurately diagnose
glaucoma. Testing for glaucoma usually involves measuring the IOP levels, observing the
optic nerve, and testing visual fields32. Results from these tests are required in order for
an ophthalmologist to make a correct glaucoma diagnosis.

2.5.1 Tonometry
Tonometry is a procedure that ophthalmologists use to measure the IOP levels25. The
Goldmann applanation tonometer is the most commonly used tool to measure IOP22 and
is considered the gold standard30,31. An anesthetic eye drop is placed into the patients’
eye, then the IOP is measured by placing a biprism plastic tip against the cornea and
flattening the cornea25. The IOP is based on the principle that the force required to flatten
a certain defined area of the cornea is proportional to the IOP25. IOP measurement is also
dependent on the thickness of the cornea22. When the cornea is thick, the IOP levels are
over estimated, and when the cornea is thin, the IOP levels are usually underestimated22.
Other less common tools to measure tonometry include the Tonopen and the Perkens;
these two tools are portable applanation tonometers25. The pascal dynamic contour
tonometer, pneumatotonometer and Schiotz tonometer are also used to measure IOP
levels25.
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2.5.2 Gonioscopy
Visualization of the anterior angle of the eye is referred to as gonioscopy8. Whether this
angle is wide or narrow affects the aqueous outflow. Gonioscopy involves examining the
angle of the anterior chamber using binocular magnification and a special
goniolens22.Several types of goniolenses are used. Goldmann and Posner-Zeiss are two
types that have mirrors to view the angle between the cornea and the iris22. The Koeppe
lens is a goniolens used with an illuminator and a handheld binocular microscope22. The
results from the gonioscopy gives an idea of whether the patient has open or closed-angle
glaucoma.

2.5.3 Ophthalmoscopy
The ophthalmoscope is a tool used to assess the optic disc. Correct evaluation of the optic
nerve head is imperative. If the optic nerve head is incorrectly classified, this can result in
a glaucoma patient remaining untreated or a non-glaucoma patient receiving treatment33.
To assess the optic disc, the ophthalmologist dilates the pupils with eye drops and uses a
slit lamp with a hand held lens to observe the optic nerve32. Evaluation of the optic nerve
requires the ophthalmologist to first assess the size of the optic nerve head26. The cup-todisc ratio is how the doctors assess the size of the optic disc22. Generally a cup size of 0.2
to 0.3 is considered normal25. The values 0.2 and 0.3 are converted into percentages;
therefore a cup size that occupies 20% to 30% of the disc is considered normal. If the
cup-to-disc ratio is greater than 0.5 with visual field loss and high IOP levels, then the
patient may have glaucoma22.

2.5.4 Perimetry
Perimetry is the measurement of visual fields25. The visual field assessment measures
both central and peripheral vision in order to find any blind spots that exist. The most
common form of perimetry is when a patient is instructed to keep one eye fixed on a
target that is directly in front of them while the other eye is covered25. The patient must
press a button every time he/she sees a light flash. The computer records the location of
the flash and whether the patient pressed the button22. This procedure examines the
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sensitivity of peripheral vision to flashes of light that are briefly presented at various
peripheral points.

2.6 Treatment of Glaucoma
Even though increased eye pressure is no longer included in the definition of glaucoma,
reduction of eye pressure remains the main form of delaying the progression of optic
nerve damage25. The primary form of treatment to prevent vision loss is
pharmacotherapy.

2.6.1 Medications
Topical medications are the first line therapy for OAG. Most glaucoma medications are
applied through eye drops or oral digestion34. There are four main classes of medications
used to lower the eye pressure. Prostaglandin analogs are currently the most popular first
line medication drugs because they have the fewest side effects25. Prostaglandin analogs
work by increasing the aqueous outflow25. Latanoprost (Xalatan) was the first
prostaglandin analog developed for glaucoma25. Travoprost (Travatan) and brimatoprost
(Lumigan) are other prostaglandin analogs. These drugs are efficient and require once a
day dose. Beta blockers, which are the second most commonly prescribed drugs, work by
decreasing the aqueous production in the eye25. They are not used as frequently as
prostaglandin analogs because they may be less effective at lowering IOP levels34. This
class of drugs works by inhibiting the sympathetic nervous system, which is involved in
the production of the aqueous humour34. Beta-blockers include Timolol, Levobunolol
(Betagan), and Betaxolol (Betoptic). Timolol is the most commonly used beta-blocker25.
Carbonic anhydrase inhibitors (CAI) are a class of drugs that work by reducing the
aqueous production by about 40-60%22. They inhibit the enzyme carbonic anhydrase
which reduces the fluid production25. The CAIs are not used frequently because they have
systemic side effects that limit their long term use22. Once the patient is taken off of this
drug, the side effects are usually reversible. These drugs are rarely used alone and are
usually prescribed in combination with other classes of drugs. Alpha agonists are another
class of drugs that decrease IOP levels by decreasing the production of fluid at the ciliary
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body and they additionally help with the aqueous outflow25. The most commonly used
drugs under this class are Brimonidine (Alphagan) and Apraclonidine (Iopidine)25.

2.6.2 Laser Therapy
Laser therapy has been gaining popularity. The first reported use of laser therapy, which
is also called laser trabeculoplasty, for patients with OAG was in the 1970s,
approximately 40 years ago35. The pressure reduction from laser therapy decreases the
medical therapy and postpones surgery, if it is required. Argon laser trabeculoplasty
(ALT) is a laser that was first introduced by Wise and Witter36 in 1979 through their pilot
study. ALT uses a spot size of 50 micrometers, between 500 and 1000 megawatts of
energy output and a pulse duration of 0.1 seconds, which is applied to the junction of the
anterior and posterior TM35. In 1983, Anderson and Parish37 found that brief pulses of
selectively absorbed optical radiation could cause damage to selected pigmented tissues.
They proposed selective photothermolysis, which made precise aiming of the laser
unnecessary because properties in the tissue provided target selectivity so that only the
pigmented tissues would be affected by the laser38. Selective laser trabeculoplasty (SLT)
was introduced in 1995 by Latina and Park11. The intention was to create a laser similar
to the argon laser, but without creating collateral damage to the non-pigmented tissue in
the TM. In 1998 Latina and colleagues12 published a pilot study and found that SLT
treatment was effective at lowering IOP in patients with or without previous ALT
treatment12. SLT is a frequency doubled, Q-switched neodymium: Yttrium-aluminium
garnet-laser (ND: YAG) with a wavelength of 532nano-meters, a pulse duration of 3
nano-seconds and a spot size of 400 micrometers 12. Because of the 3 nano-second pulse
duration in SLT compared to the 1 second pulse duration in ALT, the electromagnetic
energy in SLT does not have enough time to be converted into thermal energy, resulting
in no heat being generated39. This means that SLT does not burn the TM, and that
multiple SLT procedures are possible with minimal side effects relating to damage to the
TM.
Laser treatment works by directing the laser beam at the TM, causing the tissue to shrink,
which improves the drainage of fluid through the TM and ultimately lowers the IOP22.
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Laser treatment also stimulates the creation of new cells and helps get rid of waste in the
TM22. A theory regarding the mechanism through which the laser procedure works to
decrease the IOP is the result of cellular activity stimulated by the laser’s energy40. After
SLT is performed, there is an increase in the number of macrophages in the TM40.
Macrophages are cells that are involved in the removal of cellular debris that is generated
during tissue remodeling, and efficiently clear cells that have died41. This allows an
increased outflow of the fluid from the eye40.

2.6.2.1 Application of SLT
The ND: YAG Q-switched laser can be administered to the TM over multiple degrees of
application. The most common degrees of treatment over the TM as reported in published
studies are 90, 180, 270, or 360 degrees. Furthermore, each ophthalmologist has their
own preference on the number of laser spots to be applied, and whether to apply the laser
spots contiguously or non-contiguously. As with any other medical procedure, the
guiding principle for SLT treatment is to apply the least amount of treatment to the TM as
possible in order to achieve the desired benefit42. Several studies with mixed results have
assessed whether this difference in the application of the laser beam throughout the TM
affects the IOP-lowering effect of SLT treatment. Several studies have reported that the
SLT degree may make a difference43,44, or may not make any difference45,46 on the IOPlowering effect.

2.6.3 Surgical Treatment
If medical therapy or laser therapies do not work, surgical treatment is recommended.
Trabeculectomy is the most common form of surgical treatment (often referred to as
filtration procedure)22. This procedure reduces the IOP levels by creating another
passageway for the fluid to flow out by removing part of the TM47. Finally, when laser or
surgical treatment does not work, the ophthalmologist may decide to destroy the ciliary
body, which is responsible for aqueous humor production22.
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2.6.4 Aim of Treatment
All treatment for glaucoma patients is aimed at lowering the IOP inside the eye. The
Early Manifestation Glaucoma Trial48 found that lowering the IOP levels was linked to a
decrease in glaucoma progression, and The Ocular Hypertension Treatment
Study49concluded that IOP reduction (IOPR) lowered the chance of ocular hypertensives
to develop glaucoma. Ophthalmologists aim to select an IOP target in which no glaucoma
progression will occur; this IOP target is different for each patient since each patient
reacts to treatment differently50.Other methods, such as vascular neuroprotective or
metabolic management were conducted in animal experiments but their influence on
glaucoma progression in humans has not yet been established in randomized clinical
trials31.
Additionally, ophthalmologists need to make sure that the treatment they provide is also
reducing the IOP fluctuations. Although some studies have shown that there is no link
between IOP fluctuations and glaucoma progression48, other studies51 have shown that
there is a link. A patient who has an average IOP of 12 mm Hg and a fluctuation between
11 mm Hg and 13 mm Hg has a reduced likelihood of developing glaucomatous damage
compared to a patient who also has an average IOP of 12 mm Hg but a fluctuation
between 10 mm Hg and 16 mm Hg50.

2.6.5 Treatment Strategies
Various treatment options could be available to a patient. The first treatment option is to
put the patient on medications, and if this is unsuccessful, after at least a 4-5 week washout of medications, the patient is provided laser treatment. In this study, this is referred to
as Sequential SLT, where SLT is provided after a wash-out period of medical treatment.
The second option is to provide medications as primary treatment, and to provide SLT
while concurrently remaining on medical treatment. In this study, his is referred to as
Adjunctive SLT treatment. The majority of published studies assess the clinical outcomes
of these two groups of patients- Sequential SLT and Adjunctive SLT. The differing
effects of these two treatment strategies remains unknown. SLT could be provided as
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primary treatment and if unsuccessful, SLT is repeated or medications are given. Finally,
a patient could be prescribed a medications-only option in which prostaglandin analogs
are given as a first line of treatment, beta-blockers as a second line of treatment, CAIs as
third and alpha agonists as a fourth line of treatment. This thesis will focus on the
efficacy of SLT when it is provided as primary, sequential or adjunctive treatment and
the efficacy of medications-only treatment.

2.7 Cost of Treatment
2.7.1 Cost of Medical Therapy
Some patients prefer pharmacotherapy because it is a less invasive treatment
alternative52. Also, any side effects associated with pharmacotherapy usually cease when
the medications are discontinued. Since glaucoma is a chronic condition, treatment
becomes costly over a patient’s lifetime. If an individual is over the age of 65 and has a
valid Ontario Health Card, he/she qualifies for the Ontario Drug Benefit Plan53. The
Ontario Drug Benefit Plan covers the majority of the anti-glaucoma medications
prescribed. If an individual is not 65 yet, the Trillium Drug Program is available for
persons who have an Ontario health card54. All of the drugs that are covered by the
Ontario Drug Benefit Plan are also covered in the Trillium Drug Plan. The difference is
that someone who is under the Trillium Drug Plan is required to pay a deductible of
approximately 4% of their net income per year into this plan54. Additionally, if the
individual is employed, some employers will offer medical drug coverage.

2.7.2 Cost of Laser Treatment and Surgery
The average cost of bilateral SLT treatment at 180 degrees was $370 in 200355. The costs
of laser therapy have not changed much over the past decade. Seider et al56 found that the
average cost of bilateral SLT is approximately $675.76. Fortunately in Ontario, patients
with glaucoma at any age who are Ontario Health Insurance Plan (OHIP) covered can
receive free yearly eye examinations. Any follow-up assessments are also covered.
Furthermore, if the patient requires SLT treatment, it is completely covered through
OHIP.
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2.7.3 Cost of Medical Treatment compared to Laser Treatment
A cost comparison study was conducted by Seider et al56comparing patients who were
provided SLT treatment concurrently with medication treatment (Adjunctive SLT) and
patients who were only prescribed medications. The Adjunctive SLT group had bilateral
treatment and was required to take a 2.5 milliliters (mL) medication once a day. The
medications-only group was required to take a 5mL medication 2 to 3 times daily. They
found that when SLT was compared to brand name glaucoma medications, SLT became
less costly within one year, but when SLT was compared to generic medications, SLT
became less costly between 13 and 40 months. Stein et al1 conducted an analysis looking
at the cost effectiveness of treating OAG patients with prostaglandin analogs, laser
trabeculoplasty, or no treatment and they found that prostaglandin analogs were cost
effective and provided a better health-related quality of life. However, these results
assumed that there was perfect compliance with glaucoma medications, which is often
not the case. Further, authors concluded that if a patient did not adhere to the
medications, laser treatment would be a cost effective alternative. Finally, Lee and
Hutnik55 conducted a 6-year cost comparison of Primary SLT with medical therapy. They
found that when SLT was repeated every two years compared to mono-drug therapy, SLT
became cost effective in the second year. When a patient who received SLT treatment
every two years was compared with a patient who was on combination drug therapy, SLT
was consistently cost effective. Combination drug therapy includes patients who are on
two or more glaucoma medications. Lee and Hutnik55 reported a cost savings for SLT
patients of $206.54, $1668.84, $2992.62 over 6 years compared to patients on mono-, biand tri- drug therapy.
Based on these studies, the number of medications, as well as generic or brand name
drugs a patient is required to take determines cost effectiveness of SLT compared to
medical therapy.
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2.8 Purpose
2.8.1 Efficacy of SLT
Previously published studies have reported an average 18-40% reduction post SLT
treatment57. Latina et al12 conducted a study including 30 patients with uncontrolled OAG
and showed a 23.5% reduction from baseline at 26 weeks. Melamed et al58studied effects
of Primary SLT treatment in 45 patients diagnosed with OAG or OHT and found a 30%
reduction in IOP from baseline up until 18 months post SLT treatment. Overall, the
effectiveness of SLT has been shown to be successful through previously conducted
clinical trials11,12.

2.8.2 Previous Systematic Reviews and Meta-Analyses
To our knowledge, to date one systematic review59 and three meta-analyses60–62have been
conducted comparing SLT with topical glaucoma medications. Each study assessed the
IOP reduction, which was measured in millimeters of mercury (mm Hg).
Li et al (2015)60 conducted a meta-analysis on studies comparing SLT to topical
glaucoma medications. In total, they found five studies. The outcomes considered were
intra-ocular pressure reduction (IOPR), SLT success rate defined as achieving a 20% or
greater reduction in IOP, and complications associated with SLT. They concluded that
both SLT and topical medications provided similar reduction in IOP in patients with
OAG.
Wong et al(2014)61 performed a meta-analysis comparing SLT with ALT, and SLT with
topical glaucoma medications, and reported side effects (complications) post SLT.
Overall, they found that SLT had comparable IOP-lowering effects as medications.
Peng et al (2014)62 conducted a systematic review and meta-analysis of RCTs comparing
prostaglandin analogs to SLT. They found three studies that were included in the
analysis. Overall, their analysis showed that IOP reduction favored prostaglandin
analogs, with a WMD= [-0.85 mm Hg (95% CI-1.43, -0.27)], and no significant
heterogeneity (I2=0%, P=0.8) between studies.
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McAlinder et al (2013)63 conducted a systematic review of studies comparing SLT with
other treatment methods for glaucoma patients. A subsection of this article directly
compared SLT versus topical glaucoma medications. Authors summarized results found
in four studies and found that there was no significant difference between the two
treatment alternatives.
Li et al (2015)60, Wong et al (2014)61, and Peng et al (2014)62 conducted their metaanalyses including the same studies. Overall, two60,61of the meta-analyses showed no
difference in IOP-lowering effect between SLT and medications-only and one62 study
favored medications-only (prostaglandin analogs).
Furthermore, to the best of our knowledge, there has been no systematic review and
meta-analysis evaluating the effect of SLT as primary, sequential or adjunctive treatment.

2.8.3 Gap in Knowledge
The differences in IOP-lowering effect of patients on pharmacotherapy compared to
patients who received SLT as either sequential, adjunctive, or primary treatment remains
unknown. This systematic review and meta-analysis is aimed to explore difference in
treatment strategies. Further, this was the first study evaluating the effect of SLT on the
reduction in post-operative medications over a period of six to 60 months.
Moreover, there have been a vast number of studies that have shown SLT to be safe and
effective. If providing SLT sequentially, adjunctively or as primary treatment is more
effective at lowering IOP levels than pharmacotherapy, then this could be an impetus for
ophthalmologists to change current treatment practice for glaucoma patients. Based on
the literature, cost-analyses have concluded that the majority of patients do not adhere to
the medication instructions, which can worsen the visual field damage. By providing
SLT-a cost-effective approach from the patient’s perspective- the visual field damage that
occurs from noncompliance of the drug regimen can be prevented.
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2.8.4 Aims and Objectives
The aim of this thesis was to conduct a systematic review and meta-analysis on the
efficacy of SLT. The primary objective was to investigate the effect of SLT as primary,
sequential or adjunctive treatment on the IOP levels and on the number of medications.
The secondary objective was to assess the reported complications associated with SLT
treatment. Below are the research questions and the associated hypotheses.
Primary Research Questions:
1) Does providing SLT, as primary, sequential, or adjunctive treatment significantly
reduce the IOP levels compared to topical glaucoma medications?
Hypothesis: Providing SLT does significantly reduce the IOP levels compared to
topical glaucoma medications-only treatment.
2) Does providing SLT as an adjunctive treatment significantly reduce postoperative topical glaucoma medications?
Hypothesis: SLT does significantly reduce the post-operative glaucoma
medications.
Secondary Research Question (Exploratory):
3) What are the complications associated with SLT?
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Chapter 3

3

Methods

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) 64
were adhered to (APPENDIX 1). This systematic review was retrospectively registered
with the Review Registry of Systematic Reviews and Meta-Analyses under the unique
identifying number reviewregistry185. The methods section contains information on the
database and grey literature searches, the inclusion and exclusion criteria, screening
process, data extraction, quality assessment, quantitative measures used for the metaanalysis, publication bias and how missing data were dealt with.

3.1 Databases Searched
MEDLINE (Ovid), EMBASE (Ovid), CINAHL and Cochrane Library were searched from
January 1997 to July 2016. Six concepts: open-angle glaucoma, prostaglandin analogs,
beta-blockers, alpha agonists, carbonic anhydrase inhibitors, and selective laser
trabeculoplasty were used in the search. Articles included from MEDLINE were searched
by matching the medical subject heading (MeSH) terms with the keyword terms of the two
concepts ‘glaucoma’ and ‘selective laser trabeculoplasty’ using the Boolean operator AND
which was then combined with four classes of drugs using the Boolean operator OR. The
same search strategy was used for EMBASE and CINAHL. In EMBASE, Emtree termswhich had the same function as the MeSH terms- were used. For Cochrane library,
keywords were used since the option to input subject heading terms was not available.
APPENDIX 2 provides a detailed search strategy for each of the databases.

3.2 Grey Literature Sources
Grey literature were searched from the following databases: Web of Science-Core
Collections, BIOSIS Previews, and Scopus. The same six concepts described above were
searched. These three databases did not have subject heading options; therefore, keyword
searches were conducted.
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3.3 Inclusion and Exclusion Criteria
Articles studying human subjects over the age of 18 were included. If the age of the
subjects was not specified, then the use of the word ‘adult’ in the article was assumed to
be referring to subjects over 18 years of age. The age limit was included in some database
searches; however, not all of the databases (Cochrane Library, BIOSIS Previews, Web of
Science-Core Collections and Scopus) had the option of including these limits. English
written studies published after 1997 were included. 1997 was chosen as the cut off year
because SLT was invented by Latina and colleagues in 1995 and underwent clinical trials
beginning in 199712. Randomized clinical trials (RCTs), prospective non-RCTs, cohort,
retrospective, and observational studies were included. The articles included discussed
SLT as an intervention; the study either compared SLT directly with medications or
assessed if SLT reduced the required medications. Studies with sample size of at least 20
eyes at baseline and follow-up time points were included. Based on ophthalmic literature,
a sample size of 20 or more eyes is considered to be a good quality study. Studies with
follow-up data of at least 6 months or greater were included as the literature states that
SLT could be repeated every six months65; and we wanted to assess the IOP-lowering
effect after a point where SLT could be repeated, if necessary. Some studies provided a
follow-up time as a range, for example, 4-6 months. These studies were included in the
analysis because there was no way of separating the patients who were followed-up for
four months from those who were followed-up for six months. The study was included in
the analysis if the medications being compared to SLT were from the following four
classes: prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, or alpha
agonists. There was no restriction placed on the country in which the study was
conducted. The exclusion criteria were any studies that assessed the effect of repeat SLT
treatment and any patients that had previously undergone glaucoma surgery.

3.4 Article Screening Process
Two independent reviewers, Muna Hassan (MH) and Emaad Mohammad (EM), screened
the articles using EPPI Reviewer 466 (EPPI) (by EPPI-Centre, Social Science Research
Unit, the Institute of Education, the University of London, UK). The articles were uploaded

20

onto EPPI by converting the document into a RIS file. Once the files were uploaded from
the different databases and grey literature sources, they were screened for duplicates. We
selected the option to have EPPI automatically remove the duplicates. Each article was
assessed again to determine if there were any more duplicates. Once this was done, the
screening phase was initiated. Throughout the screening process the two screeners, MH
and EM, held frequent meetings either face-to-face, through Skype or by telephone to
merge agreements and disagreements and to resolve disagreements at each level of
screening.
In total, there were three levels of screening. Level one involved screening only the title of
the article. Articles evaluating SLT were carried on to level two screening. The articles that
were included after level two analyzed 20 or more eyes, had six months or greater followup time, and were research articles. If the abstract did not provide enough information to
answer these three questions then the ‘Unsure’ option was selected. All articles that were
recorded as ‘Unsure’ were included into the next level of screening. After level one and
two were screened, the reviewers MH and EM met to discuss any differences in results.
Level three screening involved reading the entire article. Each reviewer independently
reviewed the articles remaining in level three. All of the articles included in the analysis
either directly compared SLT with medical therapy or looked at SLT as an intervention
with the aim of examining if SLT reduced the amount of medications. Articles were
included for meta-analysis after reconciling disagreements. Level 1, 2, and 3 screening
questions are provided in APPENDIX 3.

3.4.1

Cohen’s Kappa Statistic

The Cohen’s kappa statistic was measured to determine the reliability of the data
collection method. Cohen’s kappa statistic is a measure to determine the level of interrater agreement between categorical items. It is widely used compared to the percentage
agreement statistic because it takes into account any agreement that may have occurred
by chance67. As a result, when an assessor wants to determine the inter-rater agreement,
the percentage agreement statistic is much higher than the kappa statistic.
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In the article screening process, the kappa statistic represents the extent to which the
reviewers assign the same inclusion, exclusion, or unsure decision to the same articles.
This value is calculated using the formula below:
κ=

Pr(𝑎) − Pr(𝑒)
1 − Pr(𝑒)

Pr (a) represents the observed agreement and Pr (e ) represents chance agreement67. The
kappa statistic produces a value that lies between -1 and +1. A kappa value is often
accompanied by a p-value and a confidence interval. If the kappa statistic is less than zero
then that represents less than chance agreement, 0.01- 0.02 represents slight agreement,
0.21- 0.40 represents fair agreement, 0.41- 0.60 represents moderate agreement, 0.610.80 represents substantial agreement and 0.81- 0.99 represents almost perfect
agreement68.

3.5
3.5.1

Outcomes
IOP Reduction

One of the primary outcomes was the intra-ocular pressure reduction (IOPR) from
baseline. The IOPR variable was calculated by subtracting the IOP at each follow-up time
from the reported IOP at baseline. IOP was measured in millimeters of mercury in all
included studies.

3.5.2

Medication Reduction

The other primary outcome was the reduction in medications. Each drug was defined as
one medication. For example, if a patient was taking latanoprost and timolol, in two
separate bottles, this was classified as two medications. If these two drugs were combined
in one bottle, they counted as two medications. After SLT treatment, if the patient only
required latanoprost, then this counted as one medication, and the medication reduction in
this case was one. The medication reduction was assessed as the difference in required
medications pre-and-post SLT treatment.
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3.5.3

Complications

The secondary outcome was an exploratory outcome. We gathered data on any reported
minor or major complications associated with SLT. The adverse events were reported in a
list format, and the number of times the complication was reported in other studies were
tallied and presented in a table.

3.6

Data Extraction

All data were extracted from a data extraction sheet, using Excel. The data extraction sheets
are provided in APPENDIX 4-5.

3.6.1

Baseline and Follow-up

Data on author, year of publication, study design, SLT degree, type of glaucoma, baseline
and follow-up IOP levels, type of medications used, number of patients enrolled and/or
number of eyes enrolled, and mean age at enrollment were extracted. Additionally, for
studies that assessed pre-and-post-operative medications, data were gathered on
medications taken at baseline. Follow-up data were gathered on the number of remaining
eyes, the IOP levels at each follow-up time, and medications at each follow-up time. The
extracted data were used to perform descriptive statistics and meta-analysis.

3.7 Quality Assessment
The Downs and Black69 checklist was used to assess the methodological quality in the
RCTs and non-RCTs. This checklist was selected because it was one of the few
checklists geared towards all types of study designs. The highest possible score was 32. A
higher score was indicative of better overall quality. Furthermore, the Downs and Black69
checklist is a 27-item questionnaire that is divided into five sections: Reporting, External
Validity, Bias, Confounding and Power. The five sections help pinpoint why a study’s
overall quality may have been low. Each quality assessor, Muna Hassan (MH) and
Emaad Mohammad (EM), assessed the articles individually. A meeting was held to
discuss any differences in answers; once a consensus was reached, the assessors decided
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on a final score for each article. The inter-rater reliability score was calculated using the
Kappa statistic. APPENDIX 6 provides a copy of the Downs and Black checklist.

3.8 Quantitative Measures used in the Meta-Analysis
3.8.1

Meta-Analysis

Clinical practice is becoming more and more grounded on evidence-based medicine.
Evidence-based medicine is a systematic, quantitative, preferentially experimental
approach to using medical information70. Specifically, a meta-analysis is a quantitative
synthesis of independent studies for the purpose of integrating the findings into one effect
estimate to determine if an effect exists or if an effect is positive or negative70. The
outcomes of a meta-analysis may contribute a more precise estimate of the treatment effect
or risk factor than each of the individual studies. It can also settle controversies arising
from conflicting studies.
In this study, a meta-analysis was conducted using STATA 13.071 to determine a pooled
effect estimate for the IOP reduction between patients that were treated with medicationsonly and patients that were given SLT treatment. We also conducted a meta-analysis to
determine the pooled effect estimate for the reduction in medications for patients with SLT
treatment. It was assumed that because a meta-analysis is the highest form of evidencebased medicine, these pooled results would provide a precise and bias-free estimate
compared to the individual effect estimates.

3.8.1.1

Effect Measures

The extracted mean and standard deviation (SD) of the IOP at baseline and end points
were used to compute the mean IOP reduction (𝐼𝑂𝑃𝑅), percentage of IOP reduction
(𝐼𝑂𝑃𝑅%), within group standard error (𝑆𝐸𝐼𝑂𝑃𝑅 ), and standard error of percentage of IOP
reduction (𝑆𝐸𝐼𝑂𝑃𝑅% ) using the equations below2:

IOPR  IOPbaseline  IOPendpo int

24

𝐼𝑂𝑃𝑅

𝐼𝑂𝑃𝑅% = 𝐼𝑂𝑃

𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒

* 100

2
2
𝑆𝐸𝐼𝑂𝑃𝑅 = √𝑆𝐸𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
+ 𝑆𝐸𝑒𝑛𝑑𝑝𝑜𝑖𝑛𝑡

𝑆𝐸𝐼𝑂𝑃𝑅

𝑆𝐸𝐼𝑂𝑃𝑅% = 𝐼𝑂𝑃

𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒

* 100

The SD of the percentage of IOP reduction (𝑆𝐷𝐼𝑂𝑃𝑅%) was calculated using the formula:
𝑆𝐷𝐼𝑂𝑃𝑅% = 𝑆𝐸𝐼𝑂𝑃𝑅% ×√𝑛 .
The percentage reduction in medications and the average reduction in medications were
calculated for the studies that assessed the post-operative reduction in medications.
The weighted mean difference (WMD) of the percentage of IOP reduction (𝐼𝑂𝑃𝑅%) was
the effect measure used for the forest plots comparing Sequential SLT and Adjunctive SLT
with pharmacotherapy. The WMD of the average reduction in medications was the effect
measure used for the studies that assessed the post-operative reduction in medications.
WMD was chosen as the effect size because the outcomes being analyzed were continuous
variables—IOP and medications. Each study was assigned a weight, and this weight was
multiplied by the IOP percentage reduction or reduction in medications. The values
computed after these calculations provided the overall WMD. Depending on whether the
fixed-effect or random-effects model was used, the overall WMD changed.

3.8.1.2

Heterogeneity

It is inevitable that effect estimates of independent studies would differ to some degree.
Heterogeneity tests the amount of variability between the studies being pooled together.
The variability that occurs because of the differing participants, interventions, or
outcomes studied is called clinical heterogeneity. The variability that occurs because of
the study design and risk of bias is called methodological heterogeneity72. Statistical
heterogeneity results from either clinical, methodological, or both types of heterogeneity.
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The heterogeneity value tests whether the effect estimates were different from each other
for reasons other than random chance alone.
In this study, the null hypothesis for heterogeneity was that the studies shared a common
effect size73. The values that quantified the inconsistency between the studies were the I2,
Z-value, and χ2 statistics. The I2 value was made up of the chi-squared value (χ2) minus
the degree of freedom (k-1), all divided by the chi-squared value (χ2). This value was
then multiplied by 100 to get a percentage. Higher I2 value was indicative of higher
between study heterogeneity72. Visually, one could ascertain if there was heterogeneity if
the confidence intervals of the effect estimates between the studies did not overlap. If the
I2 is less than 40% then heterogeneity is not important, I2 between 30% and 60% may
represent moderate heterogeneity, I2 between 50% and 90% may represent substantial
heterogeneity and I2 between 75% and 100% represents substantial heterogeneity72

3.8.1.3

Random-Effects and Fixed-Effect Models

In the fixed-effect model, it is assumed that there is only one true effect size for all of the
studies, and the combined effect is the estimate of this common effect size72. This model
assumes homogeneity, meaning that there are no differences in the study population;
subject selection criteria and applied treatments. In a fixed-effect model, if the sample
size is large enough, the standard error will approach zero.
On the other hand, in the random-effects model, it assumes that the true effect varies
from study to study. Each study is estimating a different effect size. The weights assigned
under the random-effects model are more evenly distributed and unlike the fixed effect
model, large studies do not dominate and smaller studies do not get overlooked 73. In the
random effects model, the studies are weighted according to the inverse of their variance
and the heterogeneity parameter70. Often, the random-effects model is used to interpret
the summary of effects when the heterogeneity is significant. In this study, effect
estimates from the random-effects model were used when the statistical heterogeneity
exceeded I2=50%.
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3.9 Subgroup Analysis
3.9.1

SLT versus Medications Studies

Subgroup analyses were conducted using the SLT versus medications studies to
determine if there was a difference in results based on the timing that the SLT procedure
was provided. The timing of the SLT procedure was separated into three groups: primary
treatment, sequential treatment and adjunctive treatment. Primary SLT referred to when
a patient was newly diagnosed with glaucoma and was receiving SLT on treatment naïve
eyes. Sequential SLT was when a patient initially was on medical treatment, was washedout of the medications for about 4-5 weeks, and then received SLT treatment. Adjunctive
SLT referred to when a patient was on pharmacotherapy treatment, and was provided
SLT while continuing with their medical treatment.

3.9.2

Adjunctive SLT Studies

Subgroup analyses were conducted using the Adjunctive SLT studies that examined the
post-operative reduction in medications. A subgroup analysis was conducted based on the
SLT degree. The purpose was to determine if a difference in the results occurred based on
the SLT degree. SLT is a laser procedure that is performed on the 360 degree trabecular
meshwork (TM) where the fluid drains from the eye. Ophthalmologists perform SLT at
varying degrees. Some ophthalmologists perform SLT on the entire TM (360 degrees),
while others perform on 270, 180, or 90 degrees of the TM. For this analysis, we
stratified the data into two groups: one group received 180 degrees of laser treatment and
the other group received 360 degrees of laser treatment.
A subgroup analysis was also conducted based on the study design. The purpose was to
determine if the design of the study had an effect on the results. The studies were stratified
into two groups: those that were randomized clinical trials (RCTs) and those that were not
RCTs.
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3.10 Sensitivity Analysis
A sensitivity analysis was conducted to examine the robustness of the results by assessing
to what extent the results are affected by a change in methods or assumptions74. In the
primary analysis for the studies comparing SLT with medications, all studies were
included irrespective of the quality. The sensitivity analysis was conducted to determine
if removing the abstracts and non-RCT studies, which had the lowest overall quality,
made an impact on the results. In the Adjunctive SLT studies that assessed the pre-andpost-operative medications, we removed the abstracts that were included in the primary
analysis to determine how much of an effect they played on the results. The reason we
removed the abstracts was because they had a lower overall quality score compared to the
full studies. After performing the sensitivity analysis, if the results did not change from
the primary analysis, then it was concluded that factors had little or no influence on the
conclusions, which means that the results are robust74

3.11 Publication Bias
The purpose of a meta-analysis is to find and synthesize all the studies that meet the
specified inclusion and exclusion criteria so that the most accurate summary effect
estimates are presented. Often times publication bias occurs because the authors do not
want to publish non-significant results70,72. Larger studies with significant results are
more likely to be published than smaller studies with non-significant results70.
Publication bias can also occur because publishers may not want to publish nonrandomized or uninteresting results70. Another reason for missing studies may be the
inclusion criteria that were created for the systematic review. Some studies could be
missed through the database searching or the article screening process.
In order to assess publication bias, a funnel plot was created with Review Manager
(RevMan)75. WMD was used as the unit of measure because the variable being analyzed
was continuous. The standard error of the WMD was calculated and plotted on the y-axis
of the graph and the WMD was plotted on the x-axis of the graph. If publication bias does
not exist, the plot is expected to have a symmetric inverted funnel shape70. The top of the
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funnel plot is occupied by larger studies with an effect size that is closer to the mean effect
size. The smaller studies occupy the bottom of the funnel plot because they usually have
larger standard errors and tend to spread across a wider range of effect estimate values.
Even though funnel plot asymmetry could be due to publication bias, there may also be
other reasons causing the asymmetry including high heterogeneity, differences in
methodological quality, language bias, and time-lag bias70.

3.12 Missing Data
The Cochrane Handbook for Systematic Reviews of Interventions (2008)72 was used to
calculate values that were not directly reported in the articles. Based on the data extraction
sheets that we created, not all of the values were directly provided by the articles. Standard
deviations that were not reported on the reduction of IOP were calculated either from the
reported p-values or range72. Studies that had important values left blank were included in
the charts, but excluded in the forest plots.
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Chapter 4

4

Results
4.1 Study Characteristics

4.1.1

SLT versus Medications Studies

Of the 31 studies, 776–82 articles compared SLT with medications. Baseline
characteristics of these 7 studies are reported in Table 1. In total, 577,78,80–82 out of the 7
studies conducted SLT at 360 degrees, one76 study performed 180 degrees, and one79
study reported results for 90, 180 and 360 degrees. All studies had the SLT laser initially
set at 0.8mJ with an increase or decrease of 0.1mJ. Six77–82 of the included studies were
randomized controlled trials (RCT).
Three77,78,81 studies provided SLT as adjunctive treatment with medical therapy.
Three79,80,82 studies provided SLT sequentially after about a 4 week wash-out period, and
one76 study provided SLT as primary and as sequential therapy. Four76,79,80,82 studies
compared SLT directly with a prostaglandin analog, and three76,79,80 studies compared
SLT with latanoprost. Three77,78,81 studies compared SLT with a combination of medical
drugs from all four classes of drugs. All additional information are provided in Table 2
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Table 1: Baseline Characteristics of Included Studies Comparing SLT with Medications
Author,
Year of
Publication

SLT Timing

Degree/(Type of
Glaucoma)

Study
Design

N (Eyes)

Medications
Group Mean
Age(SD)

SLT Group Mean
IOP(SD)

Medications
Group Mean
IOP(SD)

127

SLT
Group
Mean
Age(SD)
53.5 (14.2)

Katz et al,
201282
Lai et al,
200478
Lee et al,
201477
McIlraith et
al, 200676

Sequential

360°(POAG/OHT)

RCT

53.5 (14.2)

25 (2.2)

24.5(2.2)

Adjunctive

360°(POAG/OHT)

RCT

58

51.9 (14.7)

51.9 (14.7)

26.8 (5.6)

26.2 (4.2)

Adjunctive

360°

RCT

41

66.5(13.6)

65.5(12.7)

15.8(2.7)

14.5(2.5)

Pro nonRCT
Pro nonRCT
RCT

100

62(11)

63(11)

26 (4.3)

24.6(3.7)

87

NR

167

63(17)

63(17)

RCT

40

66.4(NR)

66.4(NR)

(POAG)

Primary

180°
(OAG)

Sequential

180°
(OAG)

Nagar,
200579

Sequential

90° , 180° and
360°(OAG/OHT)

Nagar,
200980
Tan et al,
201581

Sequential

360°

26.5(4.5)
90 °
24.5(NR)
180 ° 29.7(NR)
360 ° 30.2(NR)
26.1(4)

29.2(NR)

22.8(4.5)

(POAG/OHT)

Adjunctive

360°

RCT
156
55.5(2.7)
55.5(2.7)
20.76(3.3)
20.54(3)
(POAG/OHT)
RCT: Randomized Control Trial; Pro non-RCT:Prospective Non-RCT; NR:Not Reported; N:Number of Eyes; SD: Standard Deviation;
POAG: Primary Open-angle Glaucoma; OHT:Ocular Hypertension; OAG: Open-angle Glaucoma; SLT: Selective laser trabeculoplasy; IOP: Intra-ocular pressure
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Table 2: SLT Characteristics of Included Studies Comparing SLT with Medications
Author, Year of
Publication
Katz et al, 201282
Lai et al, 200478

Medications Directly
Before SLT
One drop of 1%
apraclonidine 1 hour
prior to treatment
-

Medications Directly After
SLT
One drop of 1%
apraclonidine and 1%
prednisolone acetate
One drop of Alphagan and
dexamethasone 0.1% and
neomycin 0.5% twice a day
for 1 day

Laser Spots, Contiguous
versus Spaced, Degree
100 laser spots over 360°
100 non-overlapping laser spots
over 360°

Medications Used

Single burst mode through 360°
of trabecular meshwork

McIlraith et al,
200676

Brimonidine 0.2% and
pilocarpine 1% 1 hour
before treatment

50(SD: 5) contiguous laser
spots over 180°

Nagar et al,
200579

One drop of
amethocaine 1%

Nagar et al,
200980

One drop of
amethocaine 1%

Tan et al, 201581

-

One drop of brimonidine
0.2% and either prednisolone
acetate 1% or ketorolac 0.5%
immediately after therapy
and Prednisolone acetate 1%
or ketorolac 1% four times a
day for 5 days
Either dexamethasone 0.1%
eye drops of ketorolac eye
drops for four times a day for
5 days
Non-steroidal antiinflammatory drops
(ketorolac tromethamine)
four times a day for 5 days
-

Prostaglandin analogs or
beta-blockers, followed by
carbonic anhydrase
inhibitors or alpha
adrenergic agonist, then
pilocarpine
Latanoprost

Lee et al, 201477

SLT: Selective laser trabeculoplasty; SD: Standard Deviation

Prostaglandin analogs
Beta-blockers, pilocarpine,
dorzolamide, and latanoprost

90°: 25-30 laser spots,
180°: 48-53 laser spots,
360°: 93-102 laser spots

Latanoprost

100(SD: 5) non-overlapping
spots over 360°

Latanoprost

360°

Prostaglandin analogs, betablockers, carbonic anhydrase
inhibitors and alpha-agonists
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4.1.2

Adjunctive SLT Studies

The baseline characteristics of the Adjunctive SLT studies are provided in Table 3. Data
gathered included author, year of publication, type of glaucoma, study design, number of eyes,
-mean age, mean number of medications, and the IOP levels at baseline. Of the 31 studies that
were finalized after level three screening, 2777,78,81,83–105 of the studies reported data on number
of medications pre-and-post SLT. Out of the 27 studies, 1677,81,83,87,89–91,95–97,99–102,105,106studies
reported data for 360 degrees of SLT treatment, 1284–86,88,92–94,98,100,103,104,106 studies reported
data on 180 degrees of SLT treatment, two105,106 studies reported data on 270 degrees.
Nine77,78,81,84,86,94,102,104,105 studies were RCTS, one85 was a partial RCT, as only patients
receiving their first laser therapy were randomly assigned. Eight89,90,95,96,98,100,103,106 studies
were retrospective chart reviews, three83,91,99 studies were observational studies, and two87,97
studies were non-randomized clinical trials. There were a total of 1,742 eyes included in the
analysis. Where the number of eyes were not reported, the number of patients were included,
and it was assumed that there was an eye from each patient included in the analysis. The
number of medications at baseline ranged from an average of 1.398 to 3.2381 medications. The
IOP levels at baseline ranged from 14.3mm Hg99 to 26.8mm Hg78. Five81,89,98,104,105 of the
studies included were abstract only. Four85–87,94 studies were conducted in Canada,
nine88,90,92,95,96,98,100,101,106 studies were conducted in USA and the remaining
1477,78,81,83,84,89,91,93,97,99,102–105 studies were conducted outside of North America. Additional
information regarding the SLT characteristics can be found in Table 4, and additional
information regarding types of medications used can be found in Table 5.
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Table 3: Baseline Characteristics of Studies Evaluating Adjunctive SLT
Author, Year of

Type of
Glaucoma

Study Design

N
(Eyes)

Mean Age
(SD)

Abdelrahman et al.
201283
Babighian et al.
201084
Birt, 200785

POAG

Prospective (SLT)

65

POAG

Bovell et al. 201186

OAG

Bruen et al.201287

OAG/OHT

Francis et al. 200588
Giocanti-Auregan et
al. 201489 (abstract)
Greninger et al.
2014106
Habib et al. 201390

OAG
OAG

Hirneib et al. 2013 91

OAG

RCT (ELT vs
SLT)
Partially RCT*
(ALT vs SLT)
RCT (ALT vs
SLT)
Non-randomized
cohort study
(SLT)
Non-RCT (SLT)
Retrospective
(SLT)
Retrospective
Case Series (SLT)
Retrospective
Review (SLT)
Observational
(SLT)
Observational
(SLT)
RCR (SLT vs
ALT)
Retrospective
case series (SLT)
RCT (SLT vs
ALT)
Retrospective
Review (1st SLT
vs repeat SLT)
Retrospective
Review (1st SLT
vs repeat SLT)
Prospective
nonrandomized
interventional
study(SLT)
RCT (SLT vs
Meds)
Retrospective
(SLT)

Publication

OAG

OAG
NTG

POAG
Juzych et al. 200492
Kara et al.2013 93

Chronic
OAG
POAG

Kent et al.201594

PXG

Khouri et al. 2014a 95

OAG

Khouri et al. 2014b96

OAG

Koucheki &
Hashemi 201297

OAG

Lai et al. 200478

OAG/
OHT
OAG

Leon et al. 200598
(abstract)

Mean
IOP (SD)

53.2(15)

Mean
Medication
(SD)
2.25(0.97)

15

67(3.2)

2.2(0.7)

23.9(0.9)

30

64(13.9)

2.9(1.2)

22.9(4.2)

89

69.7 (10.5)

2.6 (1.2)

23.8(4.8)

74

71 (10)

2.0(1.0)

21.5(0.5)

66
46

65.4(8.2)
NR

2.8(1.1)
1.6(0.8)

NR
22.8(3.8)

110

74.1(10.5)

2.6(1.07)

18.7(NR)

104

70(10)

2.03(1.01)

19.6(3.7)

68

68.5(13.3)

2.38(1.1)

18.1(5.2)

45

NR

NR

17.8(4.6)

41

71.9(8.8)

2.5(1.3)

23.9(2.6)

48

63(10)

1.9(1)

22.7(2.1)

45

72.9(9.8)

NR

23.1(4.2)

46

73(9)

1.7(0.9)

19.7(2.3)

51

NR

1.57(0.83)

19.9(3.2)

136

62.1(13.1)

2.3(0.7)

22(NR)

58

51.9(14.7)

-

26.8(5.6)

49

NR

1.3(NR)

-

18.29(NR)
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Table 3: Baseline Characteristics of Studies Evaluating Adjunctive SLT (Continued)
Author, Year of

Type of
Glaucoma

Study Design

Lee et al. 201477

OAG

Lee et al. 201599

NTG

Lowry et al.
2016100

OAG

Rebenitsch et al.
2013101
Russo et al.
2009102
Schlote &
Kynigopoulos,
2016103
Tan et al.201581
(abstract)
Zaninetti &
Ravinet, 2008104
(abstract)
Zhang et al.
2015105 (abstract)

OAG

RCT (SLT vs
Meds)
Prospective
Cohort (SLT)
Retrospective
Interventional
Comparative Case
Series (ALT vs
SLT)
RCR(SLT)
RCT (SLT vs
ALT)
Retrospective
Review (early vs
advanced OAG)
RCT(SLT vs
Meds)
RCT(SLT)

Publication

Chronic
OAG
Advanced
OAG
OAG
OAG

N (Eyes)

Mean Age
(SD)

Mean
Medication

Mean
IOP (SD)

41

66.5(13.6)

(SD)
2.3(1.1)

15.8(2.7)

41

64.7(11.9)

1.5(0.8)

14.3(3.4)

100

75.54(10.6)

2.62(1.1)

18.5(4.2)

111

70.5(10.9)

1.5(1.26)

18.9(4.5)

60

57.8(5.3)

2.3(1.3)

22.7(1.2)

36

73.8(9.7)

1.9(1.0)

22.1(4.1)

78

55.5(2.6)

3.23(0.4)

20.7 (3.3)

67

69(8)

1.44(NR)

19.2(4.7)

*drops/patient

OAG
OAG

RCT(270
degrees)
RCT(360
degrees)

67

NR

2.3(0.5)

NR

67

NR

2.1(0.4)

NR

*Partially RCT85: Patients that had undergone previous 360 degree ALT treatment, were assigned to receive SLT. Patients
with no previous laser therapy were randomized by means of a coin toss.
*In this study104, the medications were measured as the number of drops on average per patient
RCR: Retrospective Chart Review; RCT: Randomized Clinical Trial; OAG: Open-angle glaucoma; POAG: Primary Openangle Glaucoma; PXG: Pseudoexfoliative Glaucoma; NTG: Normal tension glaucoma; SLT: Selective laser trabeculoplasty;
ALT: argon laser trabeculoplasty; ELT: Excimer laser trabeculoplasty; Meds: Medications; NR: Not reported; N: Number of
eyes; vs: versus; SD: Standard deviation
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Table 4: SLT Characteristics of Studies Evaluating Adjunctive SLT
Author, Year of
Publication
Abdelrahman et al.
201283
Babighian et al. 201084
Birt, 200785
Bovell et al. 201186
Bruen et al.201287
Francis et al. 200588
Giocanti-Auregan et
al, 201489 (abstract)

Degrees

Clock-hour

Laser spots

360

-

100

180
180
180
360
180
360

50
45-55
50
60
55 (range: 49-70)
100 (SD:10)

Greninger et al.
2014106
Habib et al. 201390
Hirneib et al. 2013 91

180, 270,
360
360
360

Inferior
Inferior
Centered on
trabecular
meshwork
-

Contiguous versus
Spaced Spots
Contiguous
(adjacent)
Adjacent
Non-overlapping
Non-overlapping

94.3 (SD:49)

-

-

102 (SD:15.2)
-

Non-overlapping

Juzych et al. 200492

180

50-55

Non-overlapping
spots, adjacent

Kara et al.2013 93

180

-

Contiguous

Kent et al. 201594

180

50 applications

-

Khouri et al. 2014a 95
Khouri et al. 2014b96
Koucheki & Hashemi
201297

360
360
360

100

Non-contiguous
Non-overlapping

Leon et al. 200598
(abstract)
Lee et al.201477
Lee et al.201599
Lowry et al. 2016100

360

Nasal
trabecular
meshwork
Inferior or
nasal
Inferior or
superior
Mid-height of
trabecular
meshwork
-

-

-

360
360
180 to
360
360

-

121.8 (SD:30)
191 (SD:27.3)
95.8(SD:50.7)

-

-

-

-

360
180

Inferior

60
50-70

360

-

-

Non-overlapping
Adjacent, nonoverlapping
-

180

Inferior

-

-

270 or
360

-

-

-

Rebenitsch et al.
2013101
Russo et al. 2009102
Schlote &
Kynigopoulos, 2016103
Tan et al. 201581
(abstract)
Zaninetti & Ravinet,
2008104 (abstract)
Zhang et al, 2015105
(abstract)
SD: Standard deviation
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Table 5: Medication Details of Studies Evaluating Adjunctive SLT
Author, Year of
Publication

Medications directly
Before SLT

Medications Directly
After SLT

Abdelrahman et al,
201283

A drop of miotic
(pilocarpine nitrate 2%)
and brimonidine tartrate
0.2% (Alphagan)
Topical anesthesia with
0.4% benozinate in a
single dose solution and
1% methylcellulose on
the cornea

Prednisolone acetate
(1%) drops

Birt, 200785

One drop of
brimonidine 0.2%

Bovell et al, 201186

Apraclonidine or
brimonidine tartrate
0.2%

Bruen et al,201287
Francis et al, 200588

-

Greninger et al,
2014106

1 drop of topical
proparacaine
hydrochloride and
apraclonidine
hydrochloride 0.5%
Tetracaine (0.5% used
for anaesthesia

86% on Beta-blockers,
36% on CAI, 43% on
Alpha-agonist, 83% on
PGA, 6% on Pilocarpine
Topical prednisolone
53% PGA, 65% Betaacetate 1% for 5 days
blockers, 31% Alphaagonist, 62% CAI, 38%
Pilocarpine, 78%
Combination
PGA, B-blockers
One drop of brimonidine Beta-blockers, CAI,
tartrate 0.2% and
Alpha-agonist, PGAs,
prednisolone acetate 1% pilocarpine(10 on 1
three times daily for 4
medication, 18 on 2, 14
days
on 3, 24 on 4
medications)
1 drop of apraclonidine
hydrochloride 0.5%

Babighian et al,
201084

Hirneib et al, 2013 91
Juzych et al, 200492

Topical tetracaine or
proparacaine
hydrochloride was used
as anesthesia, eyes
pretreated with
apraclonidine 1.0%

Medications provided
for Glaucoma
Treatment
-

Topical steroid
antibiotic association
with tobramycin and
dexamethasone eye
drops four times a day
for 14 days
Fluoromethalone 0.1%
(Allergan) drops four
times daily for 5 days

53% Beta-blockers, 25%
alpha-agonists, 33%
CAI(topical), 13% CAI
(oral), 93% PGA

Flurbiprofene (0.03%)
four times a day for 3
days
Topical steroids 4 times
daily for one week

-

-
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Table 5: Medication Details of Studies Evaluating Adjunctive SLT (Continued)
Author, Year of
Publication

Medications directly
Before SLT

Medications
Directly After SLT

Kara et al,2013 93

1 drop of topical
proparacaine
hydrochloride 0.5%

1 drop of
brimonidine (0.2%)
and fluorometholong
(Flarex) eye drops 4
times a day for one
week
-

Kent et al, 201594

1 drop of brimonidine
0.2% and pilocarpine
1%
Koucheki & Hashemi 1 drop of tetracaine
201297
(0.5%) in each eye
Lai et al. 200478

One drop of 1%
apraclonidine 1 hour
prior to treatment

Lee et al.201477

-

Lee et al. 201599

-

Lowry et al, 2016100

1 drop of topical
proparacaine and
iopidine 0.5%
-

Russo et al, 2009102

Schlote &
Kynigopoulos,
2016103

Topical anesthesia with
tetracaine eye drops,
and eyes were
pretreated with
apraclonidine 1.0%

Medications provided
for glaucoma
treatment
-

-

Flourometholone
(0.1%) twice a day
for 3 days
One drop of 1%
apraclonidine and
1% prednisolone
acetate
One drop of
Alphagan and
dexamethasone 0.1%
and neomycin 0.5%
twice a day for 1 day
A drop of
brimonidine tartrate;
dexamethasone 0.1%
and neomycin 0.5%
combination eye
drop used twice a
day for 1 day
1 drop of iopidine
0.5%

75% on PGA

1 drop of topical
indomethacin 0.1% 4
times daily for 1
week
Topical non-steroidal
anti-inflammatory
eye drops 4 times a
day for 1 week

-

Beta-blockers,
Pilocarpine,
Dorzolamide, and
Latanoprost
PGA or Beta-blockers,
followed by CAIs or
Alpha-agonist, then
Pilocarpine
Alpha-agonists or PGAs
followed by topical,
CAIs, then Betablockers

-

-

PGA: Prostaglandin analogs; CAI: Carbonic Anhydrase Inhibitors; SLT: Selective laser trabeculoplasty
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4.2 Study Selection
4.2.1

Screening

EPPI Reviewer 4.0(by EPPI-Centre, Social Science Research Unit, the Institute of Education,
the University of London, UK), was used to screen the articles. Search strategies were used to
gather articles from the journal databases MEDLINE (Ovid), EMBASE (Ovid), CINAHL,
Cochrane Library and the grey literature databases including Web of Science-Core Collections,
BIOSIS Previews, and Scopus. There were 1,138 articles identified from the journal databases
and 375 articles included from the grey literature sources. One-hundred and forty eight
duplicates were removed by EPPI Reviewer 4.0 and another 48 were manually removed by the
reviewer (MH). A total of 1,317 articles were included for screening.
After screening, a total of 99 articles were included. After manually reviewing 99 articles, 31
articles met the inclusion and exclusion criteria and were included for quantitative and
qualitative analysis. Figure 1 provides a PRISMA flow diagram outlining the screening process
and the reasons for exclusion at each level.
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Figure 1: PRISMA Flow Diagram

Abbreviations: SLT= Selective laser trabeculoplasty, OAG= Open angle glaucoma, MA= Meta-analysis, SR=
Systematic review
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4.2.2

Inter-rater Agreement

At each level of screening the inter-rater reliability was calculated using the kappa
statistic. In the title and abstract screening, the percentage agreement was 89%, and the
kappa score between the two reviewers (MH and EM) was 0.53. According to the kappa
statistics guidelines, this was considered moderate agreement. Most of the differences in
the agreement were due to articles that EM marked as ‘unsure’ and MH marked as
‘exclude’. For the full text screening, the percentage agreement was 91% and the kappa
score was 0.82, which was considered almost perfect agreement.

4.3 Quality Assessment
4.3.1

Downs and Black Risk of Bias Assessment

The score for reporting information sufficiently was 7.3 out of 10, on average. The
overall score for external validity, which addressed issues of generalizability, was 2.3 out
of 3, on average. The potential bias in the measurement of the intervention and the
outcome was 4.4 out of 7, on average. The average confounding score was 2.2 out of 6.
The score for the power of the study was 0.83 out of 5 on average. The reason this value
was low was because the majority of the studies did not report on the probability of
rejecting a false null hypothesis, also referred to as the power of the study, resulting in a
score of 0. The quality scores were higher in the RCT studies with an overall score of
21.6 compared to 17.03 in all the studies. Table 6 provides a tabular form of the quality
assessment results for the clinical trials and the observational studies included in the
analysis.
The kappa statistic was used to assess the level of agreement between the individual
ratings of each assessor (MH and EM). Tables 7 provides a detailed summary of the
percentage agreement and the kappa statistic agreement for each study.
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Table 6: Downs and Black Quality Assessment Average Score for each Category
Quality Index

Overall Quality Score (31

RCTs(12 studies)

studies including RCTs and
non-RCTs)
Average

Range

Score

Average

Range

Score

Reporting

7.3

5-10

7.25

5-10

External Validity

2.3

0-3

2.08

0-3

Bias

4.4

1-6

8.1

1-6

Confounding

2.2

0-5

2.5

0-5

Power

0.83

0-5

1.67

0-5

Total

17.03 (53%)

Higher values are indicative of better performance in that category

21.6 (68%)
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Table 7: Kappa Statistics Computed for Individual Studies
Author, Year of
Publication
Abdelrahman et al, 201283
Babighian et al, 201084
Birt, 200785
Bovell et al, 201186
Bruen et al,201287
Francis et al, 200588
Giocanti-Auregan et al,
201489
Greninger et al, 2014106
Habib et al, 201390
Hirneib et al, 2013 91
Juzych et al, 200492
Kara et al,2013 93
Katz et al, 201282
Kent et al, 201594
Khouri et al, 2014a95
Khouri et al, 2014b96
Koucheki & Hashemi,
201297
Lai et al, 200478
Leon et al, 200598
Lee et al, 201477
Lee et al, 201599
Lowry et al, 2016100
McIlraith et al, 200676
Nagar et al, 200579
Nagar et al, 200980
Rebenitsch et al, 2013101
Russo et al, 2009102
Schlote & Kynigopoulos,
2016103
Tan et al, 201581
Zaninetti & Ravinet,
2008104
Zhang et al, 2015105

% Agreement

Kappa Statistic (SE)

74.0%
66.67%
55.6%
70.3%
77.78%
75%
70.3%

0.49(0.17)
0.31(0.15)
0.08(0.19)
0.30(0.14)
0.52(0.19)
0.44(0.19)
0.42(0.17)

66.67%
77.78%
77.78%
85.19%
66.6%
88.89%
70.37%
88.89%
92.59%
77.78%

0.31(0.19)
0.55(0.19)
0.56(0.17)
0.69(0.19)
0.32(0.17)
0.72(0.19)
0.41(0.31)
0.75(0.19)
0.83(0.19)
0.47(0.19)

88.89%
88.89%
70.37%
92.59%
81.48%
77.78%
85.19%
81.48%
92.59%
81.48%
74.07%

0.75(0.19)
0.74(0.19)
0.32(0.17)
0.84(0.19)
0.62(0.18)
0.47(0.19)
0.72(0.17)
0.64(0.17)
0.83(0.19)
0.58(0.19)
0.40(0.19)

92.59%
92.59%

0.82(0.19)
0.82(0.19)

92.59%

0.84(0.19)

Higher numbers are indicative of better agreement
SE: Standard Error

43

4.4 Publication bias
Figure 2 depicts the funnel plot for the studies comparing SLT with medications. If the
fixed-effect estimate is true and no bias is present, then the dotted line triangle is centered
on a fixed effect summary estimate and extends 1.96 standard errors either side and
includes about 95% of the studies72. The WMD of the percentage reduction in IOP was
plotted on the x-axis and the standard error of the WMD of the percentage reduction in
IOP was plotted on the y-axis. The standard error on the y-axis decreased as we went up
the funnel plot. None of the studies were plotted inside the pseudo 95% fixed estimate,
suggesting that heterogeneity may be present. All of the studies were plotted near the
middle and top of the funnel plot.
Figure 3 shows the funnel plot for the Adjunctive SLT studies examining pre-and-postoperative medications. The WMD of the reduction in medications was plotted on the xaxis and the standard error of the WMD of the reduction in medications was plotted on
the y-axis. The majority of the studies were located to the right of the average effect
estimate (the central line) and 8 of the 15 studies were located outside of the expected
pseudo 95% interval, suggesting heterogeneity may be present. The bottom left corner of
the funnel plot was empty, suggesting that smaller studies may not have been published.
Although publication bias may be one reason for the asymmetry, there are several other
reasons for funnel plot asymmetry which include: high heterogeneity, language bias, and
availability bias.
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Figure 2: Funnel Plot for Studies Evaluating SLT versus Medications

The standard error (SE) of the mean difference (MD) in the intra-ocular pressure
percentage reduction is plotted on the y-axis. The MD of the intra-ocular pressure
percentage reduction is plotted on the x-axis. N=7.
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Figure 3: Funnel Plot for Studies Evaluating SLT as an Adjunctive Treatment

The standard error (SE) of the mean difference (MD) in the reduction in medications is
plotted on the y-axis. The MD of the reduction in medications is plotted on the x-axis.
N=17.
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4.5 Impact on Intra-ocular Pressure Reduction (IOPR)
4.5.1

IOPR after SLT

Thirty studies provided data on the IOP reduction after SLT. Table 8 lists twenty-six of
the studies that provided SLT adjunctively with medications, and three79,80,82 studies that
provided SLT sequentially after about a 4-5 weeks wash-out of medications, and one76
study that provided SLT as primary and sequential treatment. Data were presented on the
follow-up time, number of eyes at each follow-up time, the percentage IOP reduction
(𝐼𝑂𝑃𝑅%), and the standard error of the percentage IOP reduction (𝑆𝐸𝐼𝑂𝑃𝑅%). In total there

were 2561,76,78–84,87,90–98,100,102,103,105,106 studies that reported data on 6-9 months,
2276,78,79,82–87,89,90,92,93,95,97,99–103,106 studies on 12 months follow-up, six83,84,90,95,97,99 studies
on 18 months of follow-up, nine84,86,90,92,95,99,100,104,106 studies on 24 months of follow-up,
two86,90 studies reported data on 36 months, two86,92 studies reported on 48 months and
three86,89,92 studies reported data on 60 months or greater.
The percentage IOP reduction averaged 21.3% (range: 14.3% to 40.4%) at 6-9 months,
22.4% (range: 11.8% to 43.7%) at 12 months, 17.1% (range: 11% to 20.9%) at 18
months, 17.2% (range: 11% to 23.5%) at 24 months, and 28.3% (range: 17.5% to 34.2%)
at 36 months or greater.
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Table 8:Intra-ocular Pressure Percentage Reduction Post SLT
Author, Year of
Publication

Follow-up
(months)

N (eyes)

IOP
Percentage
Reduction

SE_IOPR%

Abdelrahman et al,
201283

6
12
18
6
9
12
18
24
12
12
24
36
48
60
6
12
12
144
6
12
24
8
12
18
24
36
6 (OAG)
6 (POAG)
6
12
24
36
48
60
6 (POAG)
12 (POAG)
6 (PXG)
12(PXG)
4-6
9-12
6
8
12
18
24

65
65
65
15
15
15
15
15
30
78
79
75
72
64
56
51
NR
NR
84
80
49
79
75
65
24
18
68
45
37
32
29
25
21
20
48
48
37
37
38
29
NR
39
38
36
28

21.8%
23.4%
19.6%
19.6%
18.4%
18.8%
20.9%
20.9%
22.7%
25.2%
23.5%
28.2%
29.4%
31.1%
17.67%
21.7%
29.4%
34.2%
14.5%
11.8%
15.6%
20.5%
18%
17.7%
12.1%
17.5%
19.3%
19.3%
14.3%
18.1%
23.4%
23.4%
21.2%
27.1%
19.8%
19.3%
25.8%
27.2%
22.8%
25.0%
29.8%
21.3%
19.2%
17.7%
12.2%

.051
.052
.049
.102
.100
.100
.104
.104
.076
.049
.047
.052
.053
.058
.051
.058
.038
.036
.051
.180
.180
.180
.020
.030
.048
.048
.057
.068
.078
.078
.089
.099
.057
.056
.071
.073
.068
.080
.065
.064
.064
.062

Babighian et al, 201084

Birt, 200785
Bovell et al, 201186

Bruen et al, 201287
Giocanti-Auregan et
al, 2014 (abstract)89
Greninger et al,
2014106
Habib et al, 201390

Hirneib et al, 201391
Juzych et al, 200492

Kara et al, 201393

Katz et al, 201282
Kent et al, 201594
Khouri et al, 2014a95
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Table 8: Intra-ocular Pressure Percentage Reduction Post SLT (Continued)
Author, Year of
Publication

Follow-up (months)

N (eyes)

IOP
Percentage
Reduction

SE_IOPR%

Khouri et al, 2014b96

8
12
6
12
18
6
12
60
6

42
43
121
127
78
24
24
24
NR

20.8%
16.5%
20.0%
18.2%
17.3%
29.4%
29.4%
32.1%
14.6%

.062
.056
.036
.034
.042
.084
.084
.086
-

6
6
9
12
18
24
6
12
24
12 (Primary SLT)
12 (Sequential SLT)
6

22
34
34
34
34
34
100
100
100
74
87
90ﻩ

15.1%
21.7%
18.8%
16.0%
11.0%
11.0%
14.8%
12.14%
19.16%
31.0%
25.6%
18.3%

.076
.029
.026
.023
.016
.016
.035
.032
.040
.053
.046
.065

25.9%
40.4%
21.6%
32.6%
43.7%
23.7%
19.0%

.062
.073
.069
.067
.074
.067
-

Koucheki & Hashemi,
201297
Lai et al, 200478

Leon et al, 2005
(abstract)98

Lee et al, 201477
Lee et al, 201599

Lowry et al, 2016100

McIlraith et al, 200676
Nagar et al, 200579

4-6
12

180ﻩ
360ﻩ
90ﻩ
180ﻩ
360ﻩ
20
NR

6
12
6
12
6

43
43
36
36
78

26.0%
26.5%
26.2%
33.0%
14.5%

.066
.067
.032
.036
.039

24

36

17.2%

.062

12

Nagar et al, 200980
Rebenitsch et al,
2013101
Russo et al, 2009102
Schlote &
Kynigopoulos, 2016103
Tan et al, 2015

35
49
44
35
49
44

(abstract)81

Zaninetti & Ravinet,
2008 (abstract)
Zhang et al, 2015

6-9 (270) ﻩ
34
NR
6-9 (360) ﻩ
33
NR
NR: Not Reported; SLT: Selective laser trabeculoplasty; OAG: Open-angle Glaucoma; POAG:
Primary Open-angle Glaucoma; PXG: Pseudoexfoliative Glaucoma; N: Number of eyes; SE: Standard
Error; IOP: Intra-ocular pressure; IOPR: Intra-ocular pressure reduction
(abstract)
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4.5.2

IOPR comparing SLT versus Medications

Table 9 includes the IOP levels in both the SLT and the pharmacotherapy group. The
percentage IOP reduction and the standard error was also calculated and reported in the
table. For a follow-up time between 4-6 months, the IOP reduction averaged 24.3%
(range: 15.1% to 40.4%) in the SLT group compared to 22.6% (range: 0 to 43.5%) in the
pharmacotherapy group.
At 9-12 months of follow-up the average percentage IOP reduction was 31.0% (range:
21.6% to 43.7%) in the SLT group compared to 31.7% (range: 24.4% to 45.2%) in the
pharmacotherapy group. There was one study that gathered data up until 60 months and
the percentage IOP reduction for the SLT and medications-only group was 32.1% and
33.2%, respectively.
On average, the IOP percentage reduction was similar between the SLT group and the
medications-only group. The study by Lee et al (2014)77 reported a zero percentage
reduction at 6 months post initial medication treatment. Possible reasons include that the
baseline IOP for the pharmacotherapy group was 14.5 (2.5), which was already low.
What did change was the standard deviation (from 2.5 to 2.2), which means that the
patients in the 6 months follow-up group had IOP values closer to the mean. Tan et al
(2015)81 also reported a lower than average percentage IOP reduction (3.16%) for the
medications-only group. Reasons for this low percentage reduction could not be
identified since the full text was written in Chinese.
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Table 9:Follow-up of Included Studies Comparing SLT with Medications
Author,
Year of
Publication

FollowN of SLT
up
Group
(months)

Mean PostOperative
IOP for SLT
Group (SD)

IOP
Percentage
Reduction
for SLT
Group

SE_IOPR%
(SLT Group)

N of
Mean PostMedication Operative
Group
IOP for
Medication
Group (SD)

Katz et al
201282
Lee et al,
201477
Lai et al,
200478

4-6
9-12
6

38
29
22

18.9(2.9)
18.2(2.8)
13.4(2.3)

22.8%
25%
15.1%

.068
.080
.076

31
25
19

6
12
60
12

24
24
24
74

18.8 (NR)
18.8(NR)
18.1(NR)
17.8(3)

29.8%
29.8%
32.1%
31%

.093
.093
.095
.053

12

87

19.7(5)

25.6%

.046

6

4-6

90ﻩ
180ﻩ
360ﻩ
90ﻩ
180ﻩ
360ﻩ
20

20(NR)*
22(NR)*
18(NR)*
19.2( NR)*
20(NR)*
17(NR)*
16.4(NR)

18.3%
25.9%
40.4%
21.6%
32.6%
43.7%
23.7%

6

78

17.73(3.4)

14.5%

McIlraith et
al, 200676
[primary]
McIlraith et
al, 200676
[wash-out]
Nagar,
200579

12

Nager,
200980
Tan et al,
201581

35
49
44
35
49
44

SE_IOPR%
(Medication
Group)

17.8(3)
17.7(2.5)
14.5(2.2)

IOP
Percentage
Reduction
for
Medication
Group
27.9%
26.7%
0

24
24
24
26

19.1 (NR)
19.8 (NR)
17.5 (NR)
16.9(NR)

29.3%
28.6%
33.2%
30.6%

.092
.092
.097
.090

.065
.062
.073
.069
.067
.074
.067

39

16.5(NR)*

43.5%

.079

39

16(NR)*

45.2%

.079

20

15(NR)

34.2%

.075

.039

78

19.9(2.9)

3.16%

.019

.081
.082
-

Values with an Asterisk (*) mean that these values have not been provided by the article directly, and have been estimated from a graph
IOP: Intra-ocular pressure; IOPR: Intra-ocular pressure reduction; SD: Standard Deviation; SE: Standard Error; NR: Not reported; N: Number of eyes; SLT: Selective
laser trabeculoplasty

51

4.5.3

WMD in IOPR Comparing Sequential SLT with Medications

A forest plot was created to examine whether the timing of the SLT procedure had an effect on
IOP levels. The timing of the SLT procedure was divided into three separate groups. First, we
looked at articles that compared Sequential SLT with pharmacotherapy. Sequential SLT was
defined as SLT that was provided after a ‘wash-out’ period of about 4 weeks. During the “washout” time, patients were not receiving any glaucoma medications or treatment.
Figure 4 provides a forest plot depicting the WMD of the IOP percentage reduction in the
Sequential SLT group and pharmacotherapy group. A significant IOP percentage reduction was
seen in the pharmacotherapy group, WMD= 5.92% (95% CI [3.06, 8.79]) at 6 months follow-up
and WMD= 2.73% (95% CI [0.24, 5.23]) at 12 months follow-up. Heterogeneity between studies
that investigated the impact of Sequential SLT versus medications-only at 6 months (I2=99.9%)
and at 12 months (I2=99.8%), was significantly high (p=0.00). Therefore, the random-effects
model was computed. Furthermore, all four studies compared the Sequential SLT group with a
prostaglandin analog only medication group.
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Figure 4: Forest Plot for Studies Evaluating Sequential SLT versus Medications

Author

Year of

SLT

Sample

%

Publication

Degree

Size

WMD (95% CI)

Weight

6 months follow-up
Katz

2012

360

69

5.10 (4.91, 5.29)

25.00

McIlraith

2006

180

113

5.00 (4.87, 5.13)

25.01

Nagar

2005

360

83

3.10 (2.90, 3.30)

24.99

Nagar

2009

360

40

10.50 (10.31, 10.69)

25.00

5.92 (3.06, 8.79)

100.00

Subtotal (I-squared = 99.9%, p = 0.000)
.
12 months follow-up
Katz

2012

360

54

1.70 (1.48, 1.92)

33.31

McIlraith

2006

180

113

5.00 (4.87, 5.13)

33.37

Nagar

2005

360

83

1.50 (1.30, 1.70)

33.32

2.73 (0.24, 5.23)

100.00

Subtotal (I-squared = 99.8%, p = 0.000)
.
NOTE: Weights are from random effects analysis

-10.7

0
Favors SLT

10.7
Favors Medications
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4.5.4

WMD in IOPR Comparing Adjunctive SLT with Medications

A second forest plot was created to examine if the timing of the SLT procedure made a difference
on the IOP-lowering effect. This forest plot assessed the IOP-lowering effect comparing
Adjunctive SLT with pharmacotherapy. Adjunctive SLT was when a patient was already on
topical glaucoma medications and SLT was performed.
Figure 5 provides the forest plot of the IOP percentage reduction comparing Adjunctive SLT with
pharmacotherapy at 6 months.Three77,78,81 studies reported data at 6 months follow-up.
Significant percentage reduction in IOP in the Adjunctive SLT group, WMD= -8.98% (95% CI [17.19, -0.77]) compared to the pharmacotherapy group was seen. One78 study that had a followup of 12 months and there was a 2.3% greater reduction in IOP in Adjunctive SLT group
compared to pharmacotherapy group. Because there was only one study with a follow-up time of
12 months, this was not included in the forest plot. Heterogeneity (I2= 100%) between studies
was significantly (p=0.00) high, therefore the random-effects model was computed. All three of
the studies compared the Adjunctive SLT group to a mixed class of medications group.
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Figure 5: Forest Plot for Studies Evaluating Adjunctive SLT versus Medications at 6
months Follow-up

%

Year of

SLT

Sample

Author

Publication

Degree

Size

WMD (95% CI)

Weight

Lai

2004

360

48

-0.50 (-0.78, -0.22)

33.33

Lee

2014

360

41

-15.10 (-15.27, -14.93)

33.34

Tan

2015

360

156

-11.34 (-11.59, -11.09)

33.33

-8.98 (-17.19, -0.77)

100.00

Overall (I-squared = 100.0%, p = 0.000)

NOTE: Weights are from random effects analysis

17.2

0

-17.2
Favors SLT

Favors Medications
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4.5.5

IOPR comparing Primary SLT with Medications

One76 study assessed the effect of Primary SLT versus pharmacotherapy on the IOP reduction.
Primary SLT was defined as SLT being performed on patients with treatment naïve eyes,
meaning the patient did not have any previous medications, lasers or surgical glaucoma
treatment. The study76 found a 31% reduction in IOP in the Primary SLT group compared to a
30.6% reduction in the latanoprost-only group. More studies need to be conducted comparing
Primary SLT treatment with pharmacotherapy treatment in order to create a forest plot that
illustrates the WMD in percentage IOP reduction between the two groups. Details on this study76
can be found in Table 9.

4.6 Impact on Medications
4.6.1

Percent Reduction in Number of Medications after SLT

Of the 31 studies, there were 27 studies that looked at post-operative reduction in medications as
an outcome. Eighteen77,81,83,87,88,90–96,99,100,102,103,105,106 studies gathered data at 6-9 months followup however, only 1377,81,83,88,90,92,95,99,100,102,105,106 studies reported this data. An average 19%
(range: -4% to 55%) reduction in medications was seen. There were 1978,83,85–90,92,93,95–97,99–103,106
studies that gathered data at 12-18 months follow-up, but 1683,85,86,88–90,92,93,95,97,99–103,106,107 studies
reported this data. An average 16.1% (range: -3.8% to 64%) reduction in medications was seen.
Nine84,86,90,92,95,99,100,104,106 studies reported data on 24 months follow-up with mean reduction in
medications averaging 13.8% (range: -3.8% to 40%). Five78,86,89,90,92 studies reported data on a
follow-up of 36 months or greater with a 6.2% (range:-16.3 to 26.9%) mean reduction in
medications. The medication reductions for each study at each follow-up is reported in Table 10.
After assessing the articles, we found the three83,84,88 studies that reported the highest reduction in
medications post SLT treatment included patients with the highest initial medications. Lai et al78
reported a 16.3% increase in the medications at 60 months follow-up. This increase in
medications could be due to worsening patients’ conditions, or the effect of SLT wearing off.
Studies by Schlote & Kynigopoulos103, Rebenitsch et al.101 and Greninger et al.106 had reported
the lowest percentage reduction in medications post SLT in chronic glaucoma patients over the
age of 70.
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Table 10: Medication Reduction from Baseline in Included Studies
Author, Year of
Publication

Follow-up
(months)

N (eyes)

Mean
Medications
(SD)

Mean Reduction
in Medications
(SD)

Abdelrahman et
al, 201283

6
12
18
24

65
65
65
15

1(NR)
0.8 (NR)
1 (1.3)
0.87(0.8)

1.25(NR)
1.45(NR)
1.25(1.1)
1.33(0.3)

Mean
Percentage
Reduction in
Medications
55%
64%
55%
39.5%

12
12
24
36
48
60
6
12
6
12
12
144

30
78
79
75
72
64
56
51
66
60
NR
NR

2.2(1.6)
2.4(1.3)
2.1(1.2)
2.3(1.3)
2.1(1.2)
1.9(1.3)
NR
NR
0.7(0.9)
1.5(0.9)
1.36(0.8)
1.3(1.2)

0.7(1.1)
0.2 (0.6)
0.5 (0.5)
0.3(0.8)
0.5(0.6)
0.7(0.8)
2.1(0.5)
1.3(0.5)
0.24(- )
0.3( - )

24.1%
7.7%
19.2%
11.5%
19.2%
26.9%
25%
46.4%
15%
18.7%

6
12
24
8
12
18
24
36
6 (OAG)
6 (POAG)
6
12
24
36
48
6
12
6
8
12
18
24
8
12
16.6

84
80
49
79
75
65
45
18
68
45
37
32
29
25
21
48
48
NR
39
38
36
28
42
43
78

2.7(NR)
2.7(NR)
2.7(NR)
2.10 (1.1)
1.97 (1.1)
1.70(0.9)
1.83(1.1)
2.0(1.2)
NR
NR
2.6(1.6)
2.1(1.4)
2.3(1.4)
2.5(1.5)
2.5(1.5)
NR
2.4(1.3)
NR
1.6(0.9)
1.6(0.9)
1.5(0.8)
1.5(0.8)
NR
1.45 (0.9)
2.1(0.7)

-0.1
-0.1
-0.1
-0.07
0.06
0.33
0.2
0.03
-0.1(0.2)
0.4 (0.8)
0.2 (0.8)
0.2(1.1)
0.2(1.2)
0.5(1.3)
0.16(1.2)
0.1 (0.3)
0.1 (0.3)
0.2 (0.1)
0.2 (0.4)
0.12(0.4)
0.2(0.7)

-3.8%(increase)
-3.8%(increase)
-3.8%(increase)
-3.4%(increase)
2.9%
16.2%
9.8%
1.5%
-4%(increase)
16%
8%
8%
8%
26.3%
5.1%
5.1%
11.7%
11.7%
7.6%
8.7%

Babighian et al,
201084
Birt. 200785
Bovell et al,
201186

Bruen et al,
201287
Francis et al,
200588
Giocanti-Auregan
et al, 201489
(abstract)
Greninger et al,
2014106
Habib et al,
201390

Hirneib et al,
201391
Juzych et al,
200492

Kara et al,2013 93
Kent et al, 201594
Khouri et al,
2014a95

Khouri et al,
2014b96
Koucheki &
Hashemi. 201297
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Table 10: Medication Reduction from Baseline in Included Studies (Continued)
Author, Year of
Publication

Follow-up
(months)

N (eyes)

Mean
Medications
(SD)

Mean Reduction
in Medications
(SD)

Lai et al, 200478

12
60
6
6
6
12
24
6
12
24
12

24
24
NR
22
34
34
34
81
81
81
NR

0.46 (NR)
0.55 (NR)
NR
1.5(1.2)
1.0(1.0)
1.0(0.8)
0.9(0.9)
2.45(0.3)
2.56(0.9)
2.76(0.3)
1.5(1.1)

0
-0.09
NR
0.8(0.5)
0.5
0.5
0.6
.17(1.1 )
0.06(1.1)
-.14(1.1)
0(-)

Mean
Percentage
Reduction in
Medications
-16.3%(increase)
34.7%
33%
33%
40%
6.48%
2.3%
-5.3%(increase)
0

6
12
6
12

43
43
36
36

2.2(1.2)
2.2(1.1)
1.9(1.0)
1.9(1.0)

0.1 (0.5)
0.1 (0.5)
0
0

4.3%
4.3%
0
0

6
24

78
36

2.19(0.3)
1.36(NR)

1.04(0.3)
.08( - )

47.5%
5.5%

1(0.5)
1(0.3)

43.5%
47.6%

Leon et al, 200598
Lee et al, 201477
Lee et al, 201599

Lowry et al,
2016100
Rebenitsch et al,
2013101
Russo et al,
2009102
Schlote &
Kynigopoulos,
2016103
Tan et al, 201581
Zaninetti &
Ravinet, 2008104
Zhang et al,
2015105

drops/patient

6-9 (270°)
6-9 (360°)

34
33

1.3(0.5)
1.1(0.3)

NR: Not reported; OAG: Open-angle Glaucoma; POAG: Primary Open-angle Glaucoma; N: Number of eyes; SD: Standard
Deviation
*Lai et al, 2004: the baseline number of medications was not provided. The number of medications at 12 months was used as
the baseline to calculate the percentage reduction at 60 month
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4.6.2

WMD of Pre-and-Post SLT Medications

Figure 6 is a forest plot that illustrates the pre-and-post-operative topical glaucoma medications.
The data are divided into seven different follow-ups: 6 to 11 months, 12 to 17 months, 18
months, 24 months, 36 months, 48 months, and 60 months.
Thirteen77,81,83,88,90,92,93,95,99,100,102,103,105 studies reported 6 to 11 months follow-up,
1483,85,86,88,90,92,93,95–97,99,100,102,103 studies reported 12 to 17 months follow-up, three83,90,95 studies
reported 18 months follow-up, five86,90,92,99,100 studies reported 24 months follow-up, three86,90,92
studies reported 36 months follow-up, two86,92 studies reported 48 and 60 months follow-up.
Studies that did not report on a sample size were not included in the forest plot but were included
in the tables.
Heterogeneity between studies that reported reduction in medications at 6 to 11 months follow-up
(I2=95%, p=0.00), at 12 to 17 months follow-up (I2=86.3%, p=0.00), 18 months follow-up (I2=
88.1%, p=0.00), 24 months follow-up (I2= 68.5%, p=0.013) was significantly high. At 36 months
follow-up (I2= 0%, p=0.70), 48 months follow-up (I2= 8.1%, p=0.29), and 60 months follow-up
(I2= 46.5%, p=0.17) there was non-significant between study heterogeneity.
There was a significant reduction in post-operative medications at 6 to 11 months follow-up,
WMD= -0.55 medications (95% CI [-0.90, -0.20]), at 12 to 17 months follow-up there was also a
significant reduction, WMD= -0.32 medications (95% CI [-0.62, -0.02]). There was a nonsignificant reduction at 18 months follow-up WMD= -0.59 medications (95% CI [-1.21, 0.03]),
at 24 months follow-up WMD= -0.26 medications (95% CI [-0.58, 0.06]), at 36 months followup WMD= -0.19 medications (95% CI [-0.52, 0.13]), at 48 months follow-up WMD= -0.40
medications (95% CI [-0.79, 0.00]), and at 60 months follow-up WMD= -0.47 medications (95%
CI [-1.11, 0.18]).
Overall, there was a slight lean towards favoring SLT at all follow-up times, and there was a
significant reduction in the number of pre-and-post-operative medications at 6 to 11 months and
12 to 17 months of follow-up, however these results should be interpreted with caution as there
was high heterogeneity reported in these subgroups.
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Figure 6: Forest Plot of Medications Pre-and-Post SLT

Author

Year of
SLT
Sample
Publication Degree Size

WMD (95% CI)

6 - 11 months follow-up
Abdelrahman
2012
360
65
Francis
2005
180
66
Kara
2013
180
48
Habib
2013
360
79
Juzych
2004
180
37
Khouri
2014a
360
39
Lee
2014
360
41
Lee
2015
360
34
Lowry
2016
360
81
Russo
2009
360
43
Schlote & Kynigopoulos2015
180
27
Tan
2015
360
78
Zhang
2015
360
33
Subtotal (I-squared = 95.0%, p = 0.000)
.
12- 17 months follow-up
Abdelrahman
2012
360
65
Birt
2007
180
30
Bovell
2011
180
78
Francis
2005
180
60
Habib
2013
360
75
Juzych
2004
180
32
Kara
2013
180
48
Koucheki & Hashemi 2012
360
78
Khouri
2014a
360
38
Khouri
2014b
360
43
Lee
2015
360
34
Lowry
2016
360
81
Russo
2009
360
43
Schlote & Kynigopoulos2015
180
27
Subtotal (I-squared = 86.3%, p = 0.000)
.
18 months follow-up
Abdelrahman
2012
360
65
Habib
2013
360
65
Khouri
2014a
360
36
Subtotal (I-squared = 88.1%, p = 0.000)
.
24 months follow-up
Bovell
2011
180
79
Habib
2013
360
45
Juzych
2004
180
29
Lee
2015
360
34
Lowry
2016
360
81
Subtotal (I-squared = 68.5%, p = 0.013)
.
36 months follow-up
Bovell
2011
180
75
Habib
2013
360
18
Juzych
2004
180
25
Subtotal (I-squared = 0.0%, p = 0.708)
.
48 months follow-up
Bovell
2011
180
72
Juzych
2004
180
21
Subtotal (I-squared = 8.1%, p = 0.297)
.
60 months follow-up
Bovell
2011
180
64
Juzych
2004
180
20
Subtotal (I-squared = 46.5%, p = 0.172)
.
NOTE: Weights are from random effects analysis

%
Weight

-1.25 (-1.52, -0.98) 8.13
-2.10 (-2.37, -1.83) 8.13
0.50 (0.04, 0.96) 7.42
0.07 (-0.26, 0.40) 7.94
0.10 (-0.56, 0.76) 6.52
-0.10 (-0.50, 0.30) 7.68
-0.80 (-1.30, -0.30) 7.27
-0.50 (-0.93, -0.07) 7.56
-0.17 (-0.43, 0.09) 8.15
-0.10 (-0.63, 0.43) 7.14
-0.30 (-0.81, 0.21) 7.21
-1.04 (-1.15, -0.93) 8.46
-1.10 (-1.26, -0.94) 8.38
-0.55 (-0.90, -0.20) 100.00
-1.45 (-1.72, -1.18) 8.12
-0.70 (-1.42, 0.02) 5.76
-0.20 (-0.59, 0.19) 7.55
-0.70 (-1.01, -0.39) 7.94
-0.06 (-0.39, 0.27) 7.83
-0.40 (-1.06, 0.26) 6.06
0.50 (0.04, 0.96) 7.16
-0.20 (-1.04, 0.64) 5.13
-0.10 (-0.50, 0.30) 7.47
-0.12 (-0.48, 0.24) 7.72
-0.50 (-0.88, -0.12) 7.59
-0.06 (-0.38, 0.26) 7.89
-0.10 (-0.61, 0.41) 6.91
-0.30 (-0.81, 0.21) 6.89
-0.32 (-0.62, -0.02) 100.00
-1.25 (-1.64, -0.86) 32.90
-0.33 (-0.66, 0.00) 34.17
-0.20 (-0.59, 0.19) 32.92
-0.59 (-1.21, 0.03) 100.00
-0.50 (-0.88, -0.12) 21.53
-0.20 (-0.64, 0.24) 19.63
-0.20 (-0.90, 0.50) 12.64
-0.60 (-1.00, -0.20) 20.66
0.14 (-0.12, 0.40) 25.54
-0.26 (-0.58, 0.06) 100.00
-0.30 (-0.71, 0.11)
-0.03 (-0.75, 0.69)
0.00 (-0.78, 0.78)
-0.19 (-0.52, 0.13)

62.53
20.07
17.40
100.00

-0.50 (-0.90, -0.10) 79.11
0.00 (-0.85, 0.85) 20.89
-0.40 (-0.79, 0.00) 100.00
-0.70 (-1.14, -0.26) 66.61
0.00 (-0.90, 0.90) 33.39
-0.47 (-1.11, 0.18) 100.00

-2.37

0
Favors SLT

2.37
Disfavors SLT
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4.6.3

Subgroup Analysis by SLT Degree

A subgroup analysis was conducted to determine if the SLT degree, specifically whether SLT
was applied over 360 degrees or 180 degrees of TM, made any impact on the reduction in
medications. Figure 7 depicts a forest plot of medications pre-and-post SLT at 6 to 11 months
follow-up. There were nine77,81,83,90,95,99,100,102,105 studies that reported data on SLT preformed
over 360 degrees of the TM and there was a significant reduction in medications, WMD= -0.58
medications (95% CI [-0.89, -0.29]), with a significant between study heterogeneity (I2= 92.7%,
p=0.00). There were three88,92,103 studies that performed SLT treatment over 180 degrees of the
TM. There was a non-significant reduction in medications, WMD=-0.79 medications (95% CI [2.29, 0.71]), with significant between study heterogeneity (I2=96.8%, p=0.00).
Figure 8 depicts a forest plot reporting the WMD of the medications reduction before and after
SLT for studies that reported follow-up times from 12 to 17 months. Eight83,90,95–97,99,100,102
studies reported data for 360 degrees of SLT treatment, and there was a non-significant reduction
in medications pre-and-post SLT, WMD= -0.34 medications (95% CI [-0.77, 0.10]), with
significant between study heterogeneity (I2= 90.5%, p=0.00). Six85,86,88,92,93,103 studies reported
data for SLT preformed over 180 degrees of the TM. There was a non-significant reduction in
medications post SLT, WMD= -0.29 medications (95%CI [-0.67, 0.09]), with significant between
study heterogeneity (I2=74.2%, p=0.00).
Overall, based on the forest plots, there appeared to be a significant reduction in medications at 6
months post SLT when a patient received 360 degrees of treatment over the TM. However, by 12
months follow-up, the significant effect may ware off. Providing SLT at 180 degrees did not
appear to significantly reduce the medications at 6 months or 12 months post SLT treatment. Due
to high heterogeneity, the random effects model was used.
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Figure 7: Forest Plot of Medications Pre-and-Post SLT by SLT Degree at 6-11 Months
Follow-up

Year of
Author

Sample

%

Publication Size

WMD (95% CI)

Weight

Abdelrahman

2012

65

-1.25 (-1.52, -0.98) 11.75

Habib

2013

79

0.07 (-0.26, 0.40) 11.28

Khouri

2014a

39

-0.10 (-0.50, 0.30) 10.65

Lee

2014

41

-0.80 (-1.30, -0.30) 9.74

Lee

2015

34

-0.50 (-0.93, -0.07) 10.37

Lowry

2016

81

-0.17 (-0.43, 0.09) 11.79

Russo

2009

43

-0.10 (-0.63, 0.43) 9.46

Tan

2015

78

-1.04 (-1.15, -0.93) 12.59

Zhang

2015

33

-1.10 (-1.26, -0.94) 12.37

360 Degrees

Subtotal (I-squared = 92.7%, p = 0.000)

-0.58 (-0.89, -0.26) 100.00

.
180 Degrees
Francis

2005

66

-2.10 (-2.37, -1.83) 34.27

Juzych

2004

37

0.10 (-0.56, 0.76) 32.44

Schlote & Kynigopoulos2015

27

-0.30 (-0.81, 0.21) 33.29

Subtotal (I-squared = 96.8%, p = 0.000)

-0.79 (-2.29, 0.71) 100.00

.
NOTE: Weights are from random effects analysis

-2.37

0
Favors SLT

2.37
Disfavors SLT
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Figure 8: Forest Plot of Medications Pre-and-Post SLT by SLT Degree at 12-17 Months
Follow-up

Year of
Author

Sample

%

Publication Size

WMD (95% CI)

Weight

Abdelrahman

2012

65

-1.45 (-1.72, -1.18)13.56

Habib

2013

75

-0.06 (-0.39, 0.27) 13.19

Koucheki & Hashemi 2012

78

-0.20 (-1.04, 0.64) 9.37

Khouri

2014a

38

-0.10 (-0.50, 0.30) 12.72

Khouri

2014b

43

-0.12 (-0.48, 0.24) 13.05

Lee

2015

34

-0.50 (-0.88, -0.12)12.88

Lowry

2016

81

-0.06 (-0.38, 0.26) 13.27

Russo

2009

43

-0.10 (-0.61, 0.41) 11.96

360 Degrees

Subtotal (I-squared = 90.5%, p = 0.000)

-0.34 (-0.77, 0.10) 100.00

.
180 Degrees
Birt

2007

30

-0.70 (-1.42, 0.02) 12.89

Bovell

2011

78

-0.20 (-0.59, 0.19) 18.91

Francis

2005

60

-0.70 (-1.01, -0.39)20.41

Juzych

2004

32

-0.40 (-1.06, 0.26) 13.79

Kara

2013

48

0.50 (0.04, 0.96) 17.47

Schlote & Kynigopoulos
2015

27

-0.30 (-0.81, 0.21) 16.52

Subtotal (I-squared = 74.2%, p = 0.002)

-0.29 (-0.67, 0.09) 100.00

.
NOTE: Weights are from random effects analysis

-1.72

0
Favors SLT

1.72
Disfavors SLT
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4.6.4

Subgroup Analysis by Study Design

A subgroup analysis was conducted by study design. Figure 9 reports data for 6 to 11 months
follow-up post SLT treatment. Eight83,88,90,92,95,99,100,103 studies reported data from non-RCT
studies. The non-RCT studies showed a non-significant reduction in medications, WMD= -0.54
medications (95% CI [-1.16, 0.07]), and a significant between study heterogeneity (I2= 96%,
p=0.00). Four77,81,102,105 RCTs showed a significant reduction in medications, WMD= -0.89
medications (95% CI [-1.14, -0.63]). Heterogeneity (I2= 77.6%, p=0.00) between RCTs was
significantly high.
Figure 10 reports data for 12 to 17 months follow-up post SLT treatment. Twelve83,85,88,90,92,93,95–
97,99,100,103

studies reported data from non-RCT studies. There was a significant reduction in

medications, WMD= -0.35 medications (95% CI [-0.68, -0.01]). Heterogeneity (I2=88%, p=0.00)
between studies was significant. There were two86,102 studies that reported data from RCTs, and
there was a non-significant reduction in medications, WMD= -0.16 medications (95% CI [-0.47,
0.15]). Non-significant heterogeneity (I2=0%, p=0.76) existed between these two studies.
Based on Figures 9 and 10, RCT study results suggest a significant reduction in medications at 6
to 11 months follow-up. However, a non-significant reduction was observed at 12 to 17 months.
This conclusion is based off of two RCTs and thus more RCTs are required to make concrete
conclusions. With the non-RCT studies, a non- significant reduction in medications was observed
at 6 to 11 months follow-up, and there was a significant reduction at 12 to 17 months follow-up.
These results should not be viewed as definitive because of high heterogeneity. However, it is
important to note that the heterogeneity was lower in the RCT studies, which suggested that the
non-RCT studies may have a higher heterogeneity due to high confounding within the studies,
which the RCT studies have controlled for through randomization of participants.
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Figure 9: Forest Plot of Medications Pre-and-Post SLT by Study Design at 6-11 Months
Follow-up

Year of
Author

Sample

%

Publication Size

WMD (95% CI)

Weight

Abdelrahman

2012

65

-1.25 (-1.52, -0.98) 12.91

Francis

2005

66

-2.10 (-2.37, -1.83) 12.90

Habib

2013

79

0.07 (-0.26, 0.40) 12.75

Juzych

2004

37

0.10 (-0.56, 0.76) 11.46

Khouri

2014a

39

-0.10 (-0.50, 0.30) 12.53

Lee

2015

34

-0.50 (-0.93, -0.07) 12.42

Lowry

2016

81

-0.17 (-0.43, 0.09) 12.92

Schlote & Kynigopoulos2015

27

-0.30 (-0.81, 0.21) 12.11

Non-RCT

Subtotal (I-squared = 96.0%, p = 0.000)

-0.54 (-1.16, 0.07) 100.00

.
RCT
Lee

2014

41

-0.80 (-1.30, -0.30) 15.60

Russo

2009

43

-0.10 (-0.63, 0.43) 14.50

Tan

2015

78

-1.04 (-1.15, -0.93) 36.29

Zhang

2015

33

-1.10 (-1.26, -0.94) 33.61

Subtotal (I-squared = 77.6%, p = 0.004)

-0.89 (-1.14, -0.63) 100.00

.
NOTE: Weights are from random effects analysis

-2.37

0
Favors SLT

2.37
Disfavors SLT
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Figure 10: Forest Plot of Medications Pre-and-Post SLT by Study Design at 12-17 Months
Follow-up

Year of
Author

Sample

%

Publication Size

WMD (95% CI)

Weight

Abdelrahman

2012

65

-1.45 (-1.72, -1.18) 9.37

Birt

2007

30

-0.70 (-1.42, 0.02) 6.88

Francis

2005

60

-0.70 (-1.01, -0.39) 9.18

Habib

2013

75

-0.06 (-0.39, 0.27) 9.08

Juzych

2004

32

-0.40 (-1.06, 0.26) 7.20

Kara

2013

48

0.50 (0.04, 0.96)

Koucheki & Hashemi

2012

78

-0.20 (-1.04, 0.64) 6.19

Khouri

2014a

38

-0.10 (-0.50, 0.30) 8.70

Khouri

2014b

43

-0.12 (-0.48, 0.24) 8.96

Lee

2015

34

-0.50 (-0.88, -0.12) 8.83

Lowry

2016

81

-0.06 (-0.38, 0.26) 9.14

Schlote & Kynigopoulos2015

27

-0.30 (-0.81, 0.21) 8.09

Non-RCT

Subtotal (I-squared = 88.0%, p = 0.000)

8.38

-0.35 (-0.68, -0.01) 100.00

.
RCT
Bovell

2011

78

-0.20 (-0.59, 0.19) 63.08

Russo

2009

43

-0.10 (-0.61, 0.41) 36.92

Subtotal (I-squared = 0.0%, p = 0.760)

-0.16 (-0.47, 0.15) 100.00

.
NOTE: Weights are from random effects analysis

-1.72

0
Favors SLT

1.72
Disfavors SLT
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4.7

Impact on Adverse Events

Of the 31 included studies, 2176–79,82–86,88,89,91–94,97,100–103,106 reported on adverse events that
occurred after SLT treatment. Eleven78,79,83,84,86,88,93,97,100,102,106 studies reported an IOP spike,
ten78,79,83,86,88,93,97,100,102,106 studies reported on the number of IOP spikes observed. There were at
least 72 cases of IOP spikes among 1,742 eyes that underwent SLT, which was approximately
4.13%. All of the studies had a different definition for IOP spike. Four78,79,83,88 studies defined a
spike as an IOP greater than 5mm Hg within 24 hours of operation. Four86,97,102,106 studies defined
an IOP spike as an IOP of greater than or equal to 6mm Hg within 24 hours of operation. Lowry
et al100 defined IOP spike as an IOP greater than 7 mm Hg and Babighian et al84 stated that the
IOP spikes did not exceed 8 mm Hg. Three79,83,93 studies reported that patients experienced ocular
discomfort. The types of ocular discomfort were not described in the articles. A flare or
inflammation of the anterior chamber was reported in two76,84 studies. Five85,86,97,100,103 studies
reported that the patient required additional intervention to stabilize the IOP levels. A detailed list
of all reported complications is provided in Table 11.
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Table 11: Reported Adverse Events Post SLT Treatment
Author, Year of Publication
Abdelrahman et al, 201283

Reported Complications Post SLT

Ocular discomfort, IOP rise 1 week following SLT (5 cases), IOP
spike associated with a mild flare in the anterior chamber
Babighian et al, 201084
Flare of anterior chamber (2 cases), IOP spike (2 cases)
Birt. 200785
Trabeculectomy (5), Further laser therapy (7)
Bovell et al, 201186
IOP spike (3 cases), Additional interventions including Ahmed Valve
(5 cases), Repeat SLT (17 cases), ALT (5 cases), Trabeculectomy
Mitomycin C (14 cases), Diode cyclophotocoagulation (1 case),
Cateract extraction with intraocular lens implant/Trabeculectomy with
Mitomycin C (10 cases)
Bruen et al,201287
88
Francis et al, 2005
IOP spike (6 cases)
Giocanti-Auregan et al,201489
No significant complications
Greninger et al, 2014106
IOP spike (8 cases), cystic macular edema (1 case), Corneal epithelial
defect (1 case)
90
Habib et al, 2013
Hirneib et al, 2013 91
No adverse events after SLT
Juzych et al, 200492
Complications treated but not reported
93
Kara et al, 2013
IOP spike (7 cases), Iritis (5 cases), Ocular discomfort (16 cases)
Katz et al, 201282
No IOP elevation or uveitis, no peripheral anterior synechiae
Kent et al, 201594
Specifically no IOP spikes reported. Defined as an IOP increase of 6 or
more mm Hg after 1 hour of SLT
95
Khouri et al, 2014a
Khouri et al, 2014b96
Koucheki & Hashemi, 201297
Mild pain during SLT (23.5%), Inflammation in eyes (42.6%), IOP
spike (6 cases), Further surgical intervention (17.6%)
78
Lai et al, 2004
IOP spike (3 cases), No persistent anterior chamber reaction beyond 1
week
Leon et al, 200598
Lee et al, 201477
No complications from the laser procedure
99
Lee et al, 2015
Lowry et al, 2016100
IOP spikes (6 cases), Further surgery (9%)
McIlraith et al, 200676
Minimal inflammatory reaction (33 cases), Flare (+1) (3 cases)
Nagar et al, 200579
IOP spike (24 cases), Ocular discomfort (29 cases), mild uveitis (53
cases)
Nagar et al, 200980
Rebenitsch et al, 2013101
No adverse effects reported
Russo et al, 2009102
Anterior chamber inflammation (12 eyes), IOP spike (6 cases)
103
Schlote & Kynigopoulos, 2016
1 abnormal wound healing, trabeculecomy because of insufficient IOP
reduction (8 eyes), filtration surgery
Tan et al, 201581
Zaninetti & Ravinet, 2008104
105
Zhang et al, 2015
IOP: Intra-ocular pressure; mm Hg: millimeters of mercury; SLT: Selective laser trabeculoplasty; ALT:
Argon laser trabeculoplasty
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4.7 Sensitivity Analysis
The sensitivity analysis was conducted to examine the robustness of the results. In Figure 4,
we found that Sequential SLT versus pharmacotherapy at 6 months and 12 months follow-up
had an IOP-lowering effect that favored pharmacotherapy. We re-ran this forest plot,
excluding a study by McIlraith et al.76, and found that the results remained the same (See
Figure 11).Significant reduction in IOP was seen at 6 months in the pharmacotherapy group
compared to the Sequential SLT group, WMD= 6.23% (95% CI [1.90, 10.57]).
Heterogeneity between studies was found to be significant (I2=99.9%, p=0.00).At 12 months
a significant reduction in IOP occurred in the pharmacotherapy group compared to the
Sequential SLT, WMD= 1.60% (95% CI [1.40, 1.79]). Moderate heterogeneity (I2=42.8%,
p=0.18) was observed.
Figure 5 illustrated a forest plot of the WMD comparing Adjunctive SLT with
pharmacotherapy. At 6 months follow-up there were two full-text articles and one abstract
only, and the IOP-lowering effect favored the SLT group, WMD=-8.98% (95% CI [-17.19, 0.77]). When we re-ran the forest plot, and excluded the abstract81, we found similar results.
(See Figure 12).The WMD of Adjunctive SLT and medications-only group showed no
significant difference, WMD=-7.50% (95% CI [-22.20, 7.20]). Heterogeneity (I2= 100%,
p=0.00) was significant between studies.
Figure 6 illustrated a forest plot of the WMD of the medication reduction pre-and-post SLT.
At all follow-up times, except for 6 to 11 months and 12 to 17 months post SLT treatment,
there was a non- significant reduction in medications after SLT treatment. We re-ran the
forest plot eliminating the abstracts: Tan et al81 and Zhang et al105. This strategy produced
different results. (See Figure 13). There were 1177,83,88,90,92,93,95,99,100,102,103 studies included at
6 to11 months follow-up, 1483,85,86,88,90,92,93,95–97,99,100,102,103 studies included at 12 to 17
months follow-up, three83,90,95 studies included at 18 months follow-up, five86,90,92,99,100
studies included at 24 months follow-up, three86,90,92 studies included at 36 months followup, two86,92 studies included at 48 and 60 months follow-up.
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There was a non-significant reduction in medications at 6 to 11 months follow-up, WMD= 0.43 medications (95% CI [-0.95, 0.08]) post SLT. Significant heterogeneity (I2=95.2%,
p=0.00) was seen. At 12 to 17 months follow-up the WMD remained significant, WMD= 0.32 medications (95% CI [-0.62, -0.02]), with significant between study heterogeneity
(I2=86.3%, p=0.00). There was a non-significant reduction in medications at 18 months
follow-up, WMD= -0.59 medications (95% CI [-1.21, 0.03]) with significant between study
heterogeneity (I2= 88.1%, p=0.00), at 24 months follow-up, WMD=-0.26 medications (95%
CI [-0.58, 0.06]), with significant heterogeneity (I2= 68.5%, p=0.01). At 36 months followup a non-significant reduction in medications was seen, WMD= -0.19 medications (95% CI
[-0.52, 0.13]), with a non-significant heterogeneity (I2= 0%, p=0.70).A non-significant
reduction in medications was seen at 48 months, WMD= -0.40 medications (95% CI [-0.79,
0.00]), with a non-significant heterogeneity (I2= 8.1%, p=0.29), and WMD= -0.47
medications (95% CI [-1.11, 0.18]) at 60 months with a moderate between study
heterogeneity (I2= 46.5%, p=0.17).
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Figure 11: Sensitivity Analysis for Studies Evaluating Sequential SLT versus Medications

Author

%

Year of

SLT

Sample

Publication

Degree

Size

WMD (95% CI)

Weight

6 months follow-up
Katz

2012

360

69

5.10 (4.91, 5.29)

33.33

Nagar

2005

360

83

3.10 (2.90, 3.30)

33.33

Nagar

2009

360

40

10.50 (10.31, 10.69)

33.33

6.23 (1.90, 10.57)

100.00

Subtotal (I-squared = 99.9%, p = 0.000)
.
12 months follow-up
Katz

2012

360

54

1.70 (1.48, 1.92)

48.15

Nagar

2005

360

83

1.50 (1.30, 1.70)

51.85

1.60 (1.40, 1.79)

100.00

Subtotal (I-squared = 42.8%, p = 0.186)
.
NOTE: Weights are from random effects analysis

10.7

0

-10.7
Favors SLT

Favors Medications
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Figure 12: Sensitivity Analysis for Studies Evaluating Adjunctive SLT versus Medications

%

Year of

SLT

Sample

Author

Publication

Degree

Size

WMD (95% CI)

Weight

Lai

2004

360

48

-0.50 (-0.78, -0.22)

50.00

Lee

2014

360

41

-15.10 (-15.27, -14.93)

50.00

-7.80 (-22.11, 6.51)

100.00

Overall (I-squared = 100.0%, p = 0.000)

NOTE: Weights are from random effects analysis

22.1

0

-22.1
Favors SLT

Favors Medications
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Figure 13: Sensitivity Analysis for Studies Evaluating the Pre-and-Post SLT Number of
Medications

Author

Year of
SLT
Sample
Publication Degree Size

WMD (95% CI)

6 - 11 months follow-up
Abdelrahman
2012
360
65
Francis
2005
180
66
Kara
2013
180
48
Habib
2013
360
79
Juzych
2004
180
37
Khouri
2014a
360
39
Lee
2014
360
41
Lee
2015
360
34
Lowry
2016
360
81
Russo
2009
360
43
Schlote & Kynigopoulos2015
180
27
Subtotal (I-squared = 95.2%, p = 0.000)
.
12- 17 months follow-up
Abdelrahman
2012
360
65
Birt
2007
180
30
Bovell
2011
180
78
Francis
2005
180
60
Habib
2013
360
75
Juzych
2004
180
32
Kara
2013
180
48
Koucheki & Hashemi 2012
360
78
Khouri
2014a
360
38
Khouri
2014b
360
43
Lee
2015
360
34
Lowry
2016
360
81
Russo
2009
360
43
Schlote & Kynigopoulos2015
180
27
Subtotal (I-squared = 86.3%, p = 0.000)
.
18 months follow-up
Abdelrahman
2012
360
65
Habib
2013
360
65
Khouri
2014a
360
36
Subtotal (I-squared = 88.1%, p = 0.000)
.
24 months follow-up
Bovell
2011
180
79
Habib
2013
360
45
Juzych
2004
180
29
Lee
2015
360
34
Lowry
2016
360
81
Subtotal (I-squared = 68.5%, p = 0.013)
.
36 months follow-up
Bovell
2011
180
75
Habib
2013
360
18
Juzych
2004
180
25
Subtotal (I-squared = 0.0%, p = 0.708)
.
48 months follow-up
Bovell
2011
180
72
Juzych
2004
180
21
Subtotal (I-squared = 8.1%, p = 0.297)
.
60 months follow-up
Bovell
2011
180
64
Juzych
2004
180
20
Subtotal (I-squared = 46.5%, p = 0.172)
.
NOTE: Weights are from random effects analysis

%
Weight

-1.25 (-1.52, -0.98)9.47
-2.10 (-2.37, -1.83)9.47
0.50 (0.04, 0.96) 9.01
0.07 (-0.26, 0.40) 9.35
0.10 (-0.56, 0.76) 8.37
-0.10 (-0.50, 0.30) 9.18
-0.80 (-1.30, -0.30)8.91
-0.50 (-0.93, -0.07)9.10
-0.17 (-0.43, 0.09) 9.48
-0.10 (-0.63, 0.43) 8.81
-0.30 (-0.81, 0.21) 8.86
-0.43 (-0.95, 0.08) 100.00
-1.45 (-1.72, -1.18)8.12
-0.70 (-1.42, 0.02) 5.76
-0.20 (-0.59, 0.19) 7.55
-0.70 (-1.01, -0.39)7.94
-0.06 (-0.39, 0.27) 7.83
-0.40 (-1.06, 0.26) 6.06
0.50 (0.04, 0.96) 7.16
-0.20 (-1.04, 0.64) 5.13
-0.10 (-0.50, 0.30) 7.47
-0.12 (-0.48, 0.24) 7.72
-0.50 (-0.88, -0.12)7.59
-0.06 (-0.38, 0.26) 7.89
-0.10 (-0.61, 0.41) 6.91
-0.30 (-0.81, 0.21) 6.89
-0.32 (-0.62, -0.02)100.00
-1.25 (-1.64, -0.86)32.90
-0.33 (-0.66, 0.00) 34.17
-0.20 (-0.59, 0.19) 32.92
-0.59 (-1.21, 0.03) 100.00
-0.50 (-0.88, -0.12)21.53
-0.20 (-0.64, 0.24) 19.63
-0.20 (-0.90, 0.50) 12.64
-0.60 (-1.00, -0.20)20.66
0.14 (-0.12, 0.40) 25.54
-0.26 (-0.58, 0.06) 100.00
-0.30 (-0.71, 0.11)
-0.03 (-0.75, 0.69)
0.00 (-0.78, 0.78)
-0.19 (-0.52, 0.13)

62.53
20.07
17.40
100.00

-0.50 (-0.90, -0.10)79.11
0.00 (-0.85, 0.85) 20.89
-0.40 (-0.79, 0.00) 100.00
-0.70 (-1.14, -0.26)66.61
0.00 (-0.90, 0.90) 33.39
-0.47 (-1.11, 0.18) 100.00

-2.37

0
Favors SLT

2.37
Disfavors SLT
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4.8

Summary of Findings

Table 12 provides a summary of the main findings reported in the results.
Table 12: Summary of Main Findings
Research

Results

Interpretation

6 months post SLT treatment:

Significant difference favoring

Questions
What is the IOPlowering effect
between Sequential

the medications-only group
WMD= 5.92% (95% CI [3.06, 8.79])

SLT and
medications-only?

12 months post SLT treatment:

WMD= 2.73% (95% CI [0.24, 5.23])
What is the IOP-

6 months post SLT treatment:

lowering effect
between

Significant difference favoring
the Adjunctive SLT group

WMD= -8.98% (95% CI [-17.19, -0.77])

Adjunctive SLT
and medicationsonly?
Does SLT

6 months post SLT treatment:

significantly reduce
the number post-

medications at 6 and 12 months
WMD= -0.55 medications (95% CI [-0.90, -0.20])

operative
medications?

Significant reduction in

follow-up. All other follow-ups
showed no significant reduction

12 months post SLT treatment:

WMD= -0.32 medications (95% CI [-0.62, -0.02])
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Chapter 5
5 Discussion
5.1

Summary of Quantitative Results

The aim of this thesis was to assess the effectiveness of SLT as an intervention in adult patients
who were diagnosed with OAG or OHT. The first research question addressed whether SLT was
effective at reducing patient’s IOP levels compared to traditional pharmacotherapy. This was
based on the assessment of 689 eyes. Providing SLT adjunctively was more effective at reducing
the IOP levels than medications-only. Further, when the SLT group was ‘washed-out’ of the
medications, the IOP-lowering effect favored the medications-only group both at 6 months and
12 months follow-up. There was only one study that compared Primary SLT with
pharmacotherapy and the results showed that when SLT was provided as primary treatment, the
IOP reduction favored the SLT group.
The second research question addressed whether SLT would significantly reduce the postoperative medications. We gathered data on 1,742 eyes who underwent Adjunctive SLT
treatment. We assessed the WMD in the number of medications from baseline to 6-11, 12-17, 18,
24, 36, 46, and 60 months of follow-up. At all follow-up points, the medication reduction
favored SLT treatment; there was a significant reduction in medications post-SLT at 6 to 11
months and 12 to 17 months. However, based on the sensitivity analysis and the high
heterogeneity between the studies, concrete conclusions cannot be made.
When we conducted a subgroup analysis based on the SLT degree, we found that providing SLT
over 360 degrees of the TM significantly reduced topical glaucoma medications at 6 to 11
months follow-up, but not at 12 to17 months follow-up. Providing SLT over 180 degrees of the
TM showed no significant reduction in medications at 6 to 11 months and at 12 to 17 months
follow-up. When we conducted a subgroup analysis based on the study design, we found that the
RCTs showed a significant reduction in medications post-operatively, at 6 to 11 months followup. At 12 to 17 months follow-up the non-RCTs showed a significant reduction in medications.
There was high heterogeneity reported in the subgroup analyses and these results should not be
viewed as conclusive.
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5.2

Interpretation of Results

The majority of clinicians use a 20% IOP reduction from baseline as the determining factor for
the success of SLT treatment39. The average IOP percentage reduction was 21.3% at 6-9 months
follow-up, 22.4% at 12 months follow-up, and approximately 17% at 18-24 months follow-up. In
general, SLT provided as an adjunctive treatment, met the definition of a ‘successful’ treatment
option up until approximately 24 months, which corroborates with conclusions made in the
literature22.
A possible reason some studies reported a higher percentage IOP reduction is that their baseline
IOPs were higher. As expected, the cumulative IOP-lowering effect of multiple interventions
produced a greater IOP reduction. The Adjunctive SLT group, which consisted of patients who
were taking medications concurrently with SLT treatment, had a greater IOP reduction compared
to the pharmacotherapy group. Furthermore, this study has revealed that the order in which SLT
was provided to patients in their treatment regimen may play a role in SLT’s success.
When SLT was provided after a wash-out of medications, SLT did not have a stronger effect on
lowering IOP levels compared to medications-only group. A study conducted by Ault and
Hutnik, (2016)108 assessed a group of patients who were initially on medications. The patients
were randomized to two groups. One group of patients who were washed-out of prostaglandin
analog medications for 6 weeks, and then provided SLT, and another group who continued on
prostaglandin analog treatment. The baseline IOP was approximately 26.6 (SD: 1.6) mm Hg
before the commencement of the study. When all patients took prostaglandin analogs, their IOP
reduced to 14.5(SD: 0.6) mm Hg. The patients who were washed-out of prostaglandin analogs
for 6 weeks, their IOP rose only to 20.3(SD: 2.6) mm Hg, which was significantly lower than the
initial baseline IOP. Results from this study indicated that the impact of the prostaglandin
analogs may still be lingering in the eye well after the discontinuation of the medications; this
may be a reason why the Sequential SLT group had a smaller IOP-lowering effect. However,
more research needs to be conducted to determine the underlying reasons for this observation.
It is important to note that sometimes the intention of SLT as an additional intervention may not
be to reduce IOP by a significant amount; sometimes the intention may be to help reduce the
patient’s dependency on medications. In our analysis, on average, the studies that reported the
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greatest number of baseline medications, also reported the greatest percentage reduction in
medications, suggesting that SLT was effective at lowering medications when a patient was
taking 3 to 4 medications compared to 1 or 2 medications. Furthermore, based on the results of
this study, we could not definitively conclude which types of glaucoma medications worked best
with SLT because there were only 877,84–88,97,99 studies that reported on the type of medications
that were prescribed to the patients and the majority of the 8 studies did not provide detailed
information on how the medications were taken.
In regard to the exploratory investigation analyzing the adverse events as a result of SLT, we
found that out of the 31 studies, 21 studies mentioned adverse events post SLT. The most
commonly reported adverse events included post-operative IOP spike within 24 hours, and
ocular discomfort. These complications, as well as other complications reported, were treated
using steroids or non-steroidal anti-inflammatory eye drops39. There are some cases where SLT
cannot be performed on a patient. SLT cannot be performed when a patient has closed or very
narrow angles, severe kyphosis, ankylosing spondylosis, torticollis or cervical arthritis, head
tremors, or eyes that are deeply recessed109. With the exception of these cases where SLT cannot
be performed, SLT could be considered for OAG or OHT patients. Our results supported
previously published conclusions which have stated that there were no extreme complications
associated with SLT, suggesting that SLT was a safe procedure.

5.3

Strengths and Limitations

A major strength of this study was the research design. Systematic reviews and meta-analyses
help clinicians keep track of current data in a particular subject area by summarizing all
previously published results into one paper. This allows clinicians to make evidence-based
decisions on the best possible treatment options without having to sift through multiple research
studies. Systematic reviews provide a non-biased comprehensive review of the literature that
involves creating a search strategy to gather as many relevant articles as possible. The process of
systematically reviewing articles reduces the chance of study selection bias72. Further, in total,
the results were based on 2,431 eyes and follow-up times ranged from 4-6 months to 60 months.
A limitation of this study was the high heterogeneity. The heterogeneity reported in the forest
plots ranged from 0% to 100%. High heterogeneity meant that variations in study results were
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due to something other than chance. Possible reasons could be that there was no standard way for
SLT to be performed on patients. From study to study, SLT differed on the degree, the clock
hour the treatment was provided, the number of laser spots applied, whether or not the spots were
applied contiguously, the type of medications provided, and the anti-steroidal and antiinflammatory drugs provided directly before and after SLT treatment. Furthermore, the patients
were from differing age groups and differing stages of the disease.
A second limitation was scarce evidence. Four studies evaluated SLT sequentially, three studies
evaluated SLT adjunctively and only one study evaluated SLT as primary treatment. Even
though patients who underwent Sequential SLT were washed-out of the medications, the
lingering effect of the medications persisted, and we wanted to assess whether SLT, by itself,
without any previous medications, would result in a greater IOP-lowering effect when compared
to medications alone. The small number of relevant studies made this comparison difficult.
A third limitation was the inclusion of studies irrespective of their quality. Data were included
from non-randomized clinical trials, various observational studies, and abstracts. Ideally all
included studies would be RCTs however, due to the limited amount of studies, we could not
eliminate studies based on quality.
A fourth limitation was that we assumed that the pre-and post-operative IOP were independent.
Based on this assumption, as well as literature2, computations were conducted. Further, based on
the literature, we computed the SE_IOPR%. Given this limitation in computing the SE_IOPR%, a
potential to address this limitation in the future does exist.

5.4

Implications of Practice and Future Research

For future practice, these results suggested that providing SLT concurrently with a combination
of drugs may have the potential to reduce the medications in order to diminish non-compliance
issues. In a best case scenario, the medical treatment adherence is 75%, and when patients are
prescribed two or more medications, the adherence drops39. Patients who are non-compliant to
their treatment regimen will incur higher medical costs because their disease status will
worsen47.A study conducted by Cate et al110 found that providing an educational and
motivational support package using behavioral change counseling made no difference in
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medication adherence. Clements (2012)109 reported that telephone reminders and tailored
printing material also did not help with medication adherence.
Since the majority of the patients that underwent SLT had undergone previous medical
treatment, we could not definitively conclude how much of an independent role SLT played in
lowering the IOP. For this reason, more studies are required comparing SLT in patients with
treatment naïve eyes to SLT in patients on medications. A study conducted by Onakoya et al.111
compared SLT as primary therapy in treatment naïve eyes to patients who had SLT and
medications concurrently (Adjunctive SLT). There were 89 eyes with POAG included in the
analysis. They found a similar IOP reduction in both groups. This may suggest that just as the
Adjunctive SLT group was more effective at lowering the IOP levels than the pharmacotherapy
group in our study, the Primary SLT group may have a greater reduction in IOP compared to the
pharmacotherapy group. This could further imply that a patient would not need to take any
additional medical treatment, which could save a patient hundreds of dollars per year in medical
costs. This was only an inference and a more concrete conclusion could be made if there were
more studies comparing Primary SLT treatment with medications-only treatment.
There are currently no standardized procedures for how SLT should be administered to patients.
More studies should be conducted comparing different ways of administering SLT. Once an
ideal SLT administration is found, this method could be standardized globally. This will make
future studies that are included in meta-analysis, which aims to assess the effectiveness of SLT,
more comparable and homogenous.
Additionally, future clinical trials should provide a clear description of the types of medications
prescribed. In the studies that assessed the pre-and-post-operative medications, most studies did
not specify which types of medications were used. This information could have been imperative,
because we may have been able to determine whether SLT worked better with certain types of
drugs. Also, there need to be more studies to assess steroid or anti-inflammation drug use in the
effectiveness of SLT.
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5.5

Conclusion

This systematic review and meta-analysis concluded that SLT is an effective and safe treatment
option for patients with OAG or OHT. In addition, this study illustrated that SLT’s effectiveness
depended on when it was provided in the treatment paradigm. Out of all of the treatment
strategies that were analyzed, Adjunctive SLT was found to be more effective than
pharmacotherapy at lowering IOP levels, as well as lowering medications. Finally, since the
majority of medical drug coverage plans only pay for a portion of fees and the patient is left to
pay the difference, SLT may be the more cost effective approach since the treatment is covered
by OHIP.
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Appendix 1: PRISMA Checklist
Section/topic
TITLE
Title
ABSTRACT
Structured
Summary

#

Checklist item

Reported on
page #

1

Identify the report as a systematic review, meta-analysis, or both

i

2

Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.

ii

Describe the rationale for the review in the context of what is already known
Provide an explicit statement of questions being addressed with reference to participants,
interventions, comparisons, outcomes, and study design (PICOS).

15-17
17

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if
available, provide registration information including registration number.
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria for eligibility, giving rationale.
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
Present full electronic search strategy for at least one database, including any limits used, such that it
could be repeated.
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and,
if applicable, included in the meta-analysis).
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and
any processes for obtaining and confirming data from investigators.
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
Describe methods used for assessing risk of bias of individual studies (including specification of
whether this was done at the study or outcome level), and how this information is to be used in any
data synthesis.
State the principal summary measures (e.g., risk ratio, difference in means).

18

Describe the methods of handling data and combining results of studies, if done, including measures
of consistency (e.g., I2)for each meta-analysis.

24-26

INTRODUCTION
Rationale
3
Objectives
4
METHODS
Protocol and
registration
Eligibility criteria

5
6

Information
sources
Search

7

Study selection

9

Data collection
process
Data items

10

Risk of bias in
individual studies

12

Summary
measures
Synthesis of
results

13

8

11

14

19
18
Appendix 2
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21-23
22-23

23-24
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Appendix 1: PRISMA Checklist (Continued)

Section/topic

#

Checklist item

Risk of bias
across studies
Additional
analyses
RESULTS
Study selection

15

Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias,
selective reporting within studies).
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-specified.

Study
characteristics
Risk of bias
within studies
Results of
individual studies
Synthesis of
results
Risk of bias
across studies
Additional
analysis
DISCUSSION
Summary of
evidence
Limitations

18

Conclusions

26

FUNDING
Funding

27

16

17

Reported on
page #
27-28
27

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons
for exclusions at each stage, ideally with a flow diagram.
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, followup period) and provide the citations.
Present data on risk of bias of each study and, if available, any outcome level assessment (see item
12).
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Present results of each meta-analysis done, including confidence intervals and measures of
consistency.
Present results of any assessment of risk of bias across studies (see Item 15).

38-39

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression
[see Item 16]).

68-72

24

Summarize the main findings including the strength of evidence for each main outcome; consider
their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g.,
incomplete retrieval of identified research, reporting bias).
Provide a general interpretation of the results in the context of other evidence, and implications for
future research.

74

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of
funders for the systematic review.

103

19
20
21
22

25

29-37
40-41
46-51, 56-58,
66-67
51-54
43-45

76-77
75-76, 77-79
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Appendix 2: Search Strategy
Search Terms

MEDLINE(Ovid)
1

1.

Mesh
ocular hypertension/ or
glaucoma/ or intraocular
pressure/

2

3

2.

Keyword Search

1 or 2 Total Including Limits

4

1.

Mesh

5

2.

Keyword Search

(glaucoma* or ocular
hypertension or intraocular
pressure or intra-ocular
pressure).mp.
75069
TM/ or trabeculecomy/ or
glaucoma/
(trabeculoplast* or goniotom* or
trabeculotom* or slt or selective
laser trabeculoplast*).mp

6
7

8

9
10

11

12

4 or 5 Total Including Limits
1.

2.

Mesh

Keyword Search

7 or 8 Total Including Limits
1. Mesh

2.

Keyword Search

10 or 11 Total Including Limits

13

1.

Mesh

14

2.

Keyword Search

15
16

17
18

13 or 14 Total Including Limits
1. Mesh

2.

36552

Keyword Search

16 or 17 Including Limits

prostaglandins/ or prostaglandin/
or synthetic prostaglandin
analogs/
(Prostaglandin analogs or
Prostaglandin* or latanoprost or
bimatoprost or travoprost).mp.
116289
adrenergic beta-agonists/ or
levobunolol/ or timolol/ or
adrenergic beta-1 receptor agonists/
or betaxolol/
(Beta blocker* or B-blocker* or
Timolol or Betaxolol or
levobutonol).mp.
55062
Carbonic Anhydrase Inhibitors/ or
CAI/
(Carbonic anhydrase inhibitor* or
Carbonate dehydratase inhibitor* or
dorzolamide or brinzolamide).mp.
5113
Receptors/ or Adrenergic/ or alpha/
or exp Hypertension/ or Adrenergic
alpha-Agonists/
(Alpha-agonist* or brimonidine
or Alphagan).mp.
239,978
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19

3 AND 6 AND (9 OR 12 OR 15 OR
18)

562 Articles
The following Limits were applied:
-19 plus years of age
-Article published after 1997
-Human Subjects
-English Articles
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Search Terms

EMBASE (Ovid)
1

1.

Emtree

2

2.

Keyword Search

3
4

1 or 2

5

1.

6

4 or 5

Emtree

7

8

1.

9

7 or 8

Keyword Search

21591
prostaglandin/ or prostaglandin
analog/

Keyword Search

(Prostaglandin analogs or
prostaglandin* or latanoprost or
bimatoprost or travoprost).mp.

1.

Emtree

11

2.

Keyword Search

10 or 11

13

1.

Emtree

14

2.

Keyword Search

15

13 or 14

16

1.

Emtree

17

2.

Keyword

18

16 OR 17

19

107,631
Trabeculoplasty/ or laser therapy/
or selective laser trabeculectomy/ or
SLT/
(Trabeculoplast* or gonotom* or
trabeculectom* or slt or selective
laser trabeculoplast*).mp.

Emtree

10

12

glaucoma/ or intraocular pressure/
or ocular hypertension/
(glaucoma* or ocular hypertension
or intraocular pressure or intraocular pressure).mp.

(3 AND 6) AND ( 9 OR 12 OR 15
OR 18)
limit 21 to (human and english
language and yr="1997 -Current"
and (adult <18 to 64 years> or aged
<65+ years>))

173879
exp beta adrenergic receptor
blocking agent/ or exp atenolol/ or
exp hypertension/
(Beta blocker or b-blockers or
timolol or betaxolol or
levobutonol).mp.
805233
Carbonate Anhydrase inhibitor/ or
CAI/ or CAIS/
(carbonic anhydrase inhibitor* or
carbonate dehydratase inhibitor*
or dorxolamide or
brinzolamide).mp
6195
Alpha agonist/ or adrenergic alphaagonist/ or alpha-adrenergic
agonist/
(Alpha-agonist* or brimonidine
or Alphagan).mp.
12518
550 Articles were extracted from
Embase.
The following restrictions were
applied:
-English articles
-1997-Human Adults 18+
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Search Terms

CINAHL
1

1.

2

2.

3
4
5

1 or 2
1.
2.

6
7

4 or 5
1.

8

2.

9
10

7 or 8
1.

11

2.

12
13

10 or 11
1.

14

2.

15
16

13 or 14
1.

17

2.

18
19

16 or 17
[3 AND 6] AND [ 9 OR 12 OR 15
OR 18]

(MM "Intraocular Pressure") OR
(MM "Ocular Hypertension") OR
(MM "Glaucoma")
(Glaucoma* OR
Ocular hypertension OR intraocular
pressure OR intra-ocular pressure)
(MH "Laser Therapy")
(Trabeculoplast* OR
Goniotom* OR
Trabeculotom* OR
SLT )
(MH "Prostaglandins, Synthetic+")
OR (MH "Prostaglandins I") OR
(MH "Prostaglandins E") OR (MH
"Prostaglandins")
Prostaglandin analogs OR
Prostaglandin* OR latanoprost OR
bimatoprost OR travoprost
(MH "Adrenergic Beta-Agonists")
OR (MH "Timolol") OR (MH
"Levobunolol Hydrocholoride") OR
(MH "Betaxolol Hydrochloride")
(Beta blocker OR B-blocker OR
Timolol OR Betaxolol OR
Levobutonol)
(MH "Acetazolamide") OR (MH
"Brinzolamide") OR (MH
"Methazolamide") OR (MH
"Dichlorphenamide") OR (MH
"Dorzolamide Hydrochloride")
(Carbonic anhydrase inhibitor* OR
Carbonate dehydratase
inhibitor*OR dorzolamide OR
brinzolamide)
(MH "Brimonidine TartrateTimolol Maleate") OR (MH
"Adrenergic Alpha-Agonists")
Alpha-agonist* OR brimonidine
OR Alphagan
13 articles were included from this
database with the following limits
-English only
-published 1997-adult humans 19+

97

Cochrane Library

Search Terms

Term 1

Glaucoma* OR
Ocular hypertension OR intraocular
pressure OR intra-ocular pressure

Term 2

Trabeculoplast* OR
Goniotom* OR
Trabeculotom* OR
SLT

Term 3

Prostaglandin analogs OR
Prostaglandin* OR latanoprost OR
bimatoprost OR travoprost

Term 4

Beta blocker OR B-blocker OR
Timolol OR Betaxolol OR
Levobutonol

Term 5

Carbonic anhydrase inhibitor* OR
Carbonate dehydratase
inhibitor*OR dorzolamide OR
brinzolamide

Term 6

Alpha-agonist* OR brimonidine
OR Alphagan
Combined (Term 1 OR Term 2)
AND (Term 3 OR 4 OR 5 OR 6)

13 articles included from this
database using the above search
strategy. The following limits were
applied:
-published 1997Other limits were not applied
because the options were not
provided.
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Grey Literature Sources
BIOSIS Previews (67)

Search Strategy
#1.“TOPIC: (glaucoma* or ocular hypertension or
intraocular pressure or intra-ocular
pressure) AND TOPIC: (trabeculoplast* or goniotom*
or trabeculotom* or slt or selective laser
trabeculoplast)
Indexes=BIOSIS Previews Timespan=1997-2016”
(516 articles)
#2. “TOPIC: (Prostaglandin analogs or Prostaglandin*
or latanoprost or bimatoprost or
travoprost) OR TOPIC: (Beta blocker* or B-blocker*
or Timolol or Betaxolol or
levobutonol) OR TOPIC: (Carbonic anhydrase
inhibitor* or Carbonate dehydratase inhibitor* or
dorzolamide or brinzolamide) OR TOPIC: (Alphaagonist* or brimonidine or Alphagan)
Indexes=BIOSIS Previews Timespan=1997-2016”
(82,787 articles)
#2 AND #1
Refined by: LANGUAGES: ( ENGLISH )
Indexes=BIOSIS Previews Timespan=1997-2016

Web of Science, Core Collection (115)

#1.”TOPIC: ((glaucoma* or ocular hypertension or
intraocular pressure or intra-ocular
pressure)) AND TOPIC: ((trabeculoplast* or
goniotom* or trabeculotom* or slt or selective laser
trabeculoplast*))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S,
CPCI-SSH, ESCI Timespan=1997-2016”
#2.“TOPIC: (Prostaglandin analogs OR Prostaglandin*
OR latanoprost OR bimatoprost OR
travoprost) OR TOPIC: ((Beta blocker OR B-blocker
OR Timolol OR Betaxolol OR
Levobutonol)) OR TOPIC: ((Carbonic anhydrase
inhibitor* OR Carbonate dehydratase inhibitor*OR
dorzolamide OR brinzolamide)) OR TOPIC: (Alphaagonist* OR brimonidine OR Alphagan)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S,
CPCI-SSH, ESCI Timespan=1997-2016”
#2 AND #1
Limits: 1997-present, English Only

Scopus (193)

(SLT AND glaucoma OR (Prostaglandin OR Betablockers OR CAIS OR Alpha-agonist) )
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Appendix 3: Screening Questions

Level 1 (title screening):
Does the article look at Selective Laser Trabeculoplasty (SLT) OR SLT AND Beta-Blockers OR
Prostaglandin analogs OR Carbonic anhydrase Inhibitors, Alpha-agonist and or Open-angle
glaucoma?
Yes
No
Unclear

Level 2 (abstract screening):
Are there 20 or more patients/eyes included in the study?
Yes
No
Unclear
Is there a follow-up time of greater than 6 months?
Yes
No
Unclear

Is it a research article (exclude systematic reviews and meta-analyses)? (Not an editorial, pilot
study, or opinion)?
Yes
No
Unclear
Level 3 (full article screening):
Does the study look at SLT compared with medical therapy or does it look at the effect of SLT
on number of medications?
Yes
No
Unclear
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Appendix 4: Data Extraction Sheet for Studies Evaluating SLT versus Medications

Author

year

Slttime

Followuptime

sltdegree

n

M_siopr

Sd_siopr

n

m_miopr

Appendix 5: Data Extraction Sheet for Studies Evaluating SLT as an Adjunctive
Treatment

Author

year

sltdegree

Followuptime

n

m_mpre

sd_mpre

m_mpost

sd_mpost

Sd_miopr
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Appendix 6: Downs and Black Checklist
Description of Criteria
Reporting 1
2
3
4
5
6
7
8
9
10

External
Validity

11

12

13

Internal
ValidityBias

14

Possible
Answers
Is the hypothesis/aim/objective of the study clearly described? Yes/No
Are the main outcomes to be measured clearly described in
Yes/No
the Introduction or Methods section?
Are the characteristics of the patients included in the study
Yes/No
clearly described?
Are the interventions of interest clearly described?
Yes/No
Are the distributions of principal confounders in each group
of subjects to be compared clearly described?
Are the main findings of the study clearly described?
Yes/No
Does the study provide estimates of the random variability in Yes/No
the data for the main outcomes?
Have all important adverse events that may be a consequence Yes/No
of the intervention been reported?
Have the characteristics of patients lost to follow-up been
Yes/No
described?
Have actual probability values been reported (e.g. 0.035
Yes/No
rather than rather than <0.05) for the main outcomes except
where the probability value is less than 0.001?
Were the subjects asked to participate in the study
Yes/No/UTD
representative of the entire population from which they were
recruited?
Were those subjects who were prepared to participate
Yes/No/UTD
representative of the entire population from which they were
recruited?
Were the staff, places, and facilities where the patients were
Yes/No/UTD
treated, representative of the treatment the majority of patients
receive?
Was an attempt made to blind study subjects to the
Yes/No/UTD
intervention they have received?

15 Was an attempt made to blind those measuring the main
Yes/No/UTD
outcomes of the intervention?
16 If any of the results of the study were based on “data
Yes/No/UTD
dredging”, was this made clear?
17 In trials and cohort studies, do the analyses adjust for different Yes/No/UTD
lengths of follow-up of patients, or in case control studies, is
the time period between the intervention and outcome the
same for cases and controls?
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Appendix 6: Downs and Black Quality Checklist (Continued)
18 Were the statistical tests used to assess the main outcomes
appropriate?
19 Was compliance with the intervention/s reliable?
20 Were the main outcome measures used accurate (valid and
reliable)?
Internal
21 Were the patients in different intervention groups (trials
Validityand cohort studies) or were the cases and controls (caseConfounding
control studies) recruited from the same population?
(selection
bias)
22 Were study subjects in different intervention groups (trials
and cohort studies) or were the cases and controls (casecontrol studies) recruited over the same period of time?
23 Were study subjects randomised to intervention groups?
24 Was the randomised intervention assignment concealed
from both patients and health care staff until recruitment
was complete and irrevocable?
25 Was there adequate adjustment for confounding in the
analyses from which the main findings were drawn?
26 Were losses of patients to follow-up taken into account?
27 Did the study have sufficient power to detect a clinically
important effect where the probability value for a
difference being due to chance
UTD: Unable to Determine

Yes/No/UTD
Yes/No/UTD
Yes/No/UTD
Yes/No/UTD

Yes/No/UTD

Yes/No/UTD
Yes/No/UTD

Yes/No/UTD
Yes/No/UTD
1-5
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